NDR1
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Y Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A6NMY6 | S164 | Sugiyama | ANXA2P2 ANX2L2 ANX2P2 LPC2B | NRVyKEMYKtDLEKDIIsDtsGDFRKLMVALAKGRRAEDGS |
| O00488 | S98 | Sugiyama | ZNF593 ZT86 | THFRSKDHKKRLKQLsVEPysQEEAERAAGMGSYVPPRRLA |
| O14980 | S1055 | SIGNOR|PSP|Sugiyama | XPO1 CRM1 | LEEREIALRQADEEKHKRQMsVPGIFNPHEIPEEMCD____ |
| O60814 | S37 | Sugiyama | H2BC12 H2BFT HIRIP1 HIST1H2BK | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| O60814 | S39 | Sugiyama | H2BC12 H2BFT HIRIP1 HIST1H2BK | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| P00338 | S161 | Sugiyama | LDHA PIG19 | DILTYVAWKISGFPKNRVIGsGCNLDsARFRyLMGERLGVH |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04075 | S46 | Sugiyama | ALDOA ALDA | PGKGILAADEstGsIAKRLQsIGtENtEENRRFyRQLLLtA |
| P04083 | S173 | Sugiyama | ANXA1 ANX1 LPC1 | NRVYREELKRDLAKDItsDtsGDFRNALLsLAKGDRsEDFG |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04792 | S78 | Sugiyama | HSPB1 HSP27 HSP28 | LPPAAIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVs |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P06733 | S27 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | HAREIFDsRGNPtVEVDLFtsKGLFRAAVPsGAstGIyEAL |
| P06899 | S37 | Sugiyama | H2BC11 H2BFR HIST1H2BJ | KAVTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGISS |
| P07195 | S162 | Sugiyama | LDHB | DILTYVTWKLSGLPKHRVIGsGCNLDsARFRyLMAEKLGIH |
| P07195 | T323 | Sugiyama | LDHB | sVINQKLKDDEVAQLKKsADtLWDIQKDLKDL_________ |
| P07355 | S164 | Sugiyama | ANXA2 ANX2 ANX2L4 CAL1H LPC2D | NRVyKEMYKtDLEKDIIsDtsGDFRKLMVALAKGRRAEDGs |
| P07814 | S335 | Sugiyama | EPRS1 EPRS GLNS PARS QARS QPRS PIG32 | PIEKNLQMWEEMKKGsQFGQsCCLRAKIDMSSNNGCMRDPt |
| P07864 | S161 | Sugiyama | LDHC LDH3 LDHX | DILTYIVWKISGLPVTRVIGsGCNLDsARFRYLIGEKLGVH |
| P07900 | S53 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | IINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKLDsG |
| P07900 | Y284 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | DEEEEKKDGDKKKKKKIKEKyIDQEELNKtKPIWtRNPDDI |
| P08238 | Y276 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | DEEDDsGKDKKKKTKKIKEKyIDQEELNKtKPIWtRNPDDI |
| P11142 | T163 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | VVtVPAyFNDsQRQAtKDAGtIAGLNVLRIINEPtAAAIAy |
| P13639 | S23 | Sugiyama | EEF2 EF2 | NFtVDQIRAIMDKKANIRNMsVIAHVDHGKStLtDsLVCKA |
| P13861 | S99 | Sugiyama | PRKAR2A PKR2 PRKAR2 | EsEEDEDLEVPVPsRFNRRVsVCAEtyNPDEEEEDTDPRVI |
| P14314 | S126 | Sugiyama | PRKCSH G19P1 | yNsGVICENtCKEKGRKEREsLQQMAEVtREGFRLKKILIE |
| P14618 | T50 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | MCRLDIDsPPItARNtGIICtIGPAsRsVEtLKEMIKsGMN |
| P14625 | S514 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | LGVIEDHsNRtRLAKLLRFQssHHPtDItsLDQyVERMKEK |
| P18621 | T79 | Sugiyama | RPL17 | PFRRYNGGVGRCAQAKQWGWtQGRWPKKSAEFLLHMLKNAE |
| P22059 | S379 | Sugiyama | OSBP OSBP1 | FFDAPEIITMPENLGHKRtGsNIsGAssDIsLDEQyKHQLE |
| P23526 | S183 | Sugiyama | AHCY SAHH | NLyKMMANGILKVPAINVNDsVtKsKFDNLyGCRESLIDGI |
| P23527 | S37 | Sugiyama | H2BC17 H2BFH H2BFN HIST1H2BO | KAVTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGISS |
| P26373 | S181 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | YKKEKARVItEEEKNFKAFAsLRMARANARLFGIRAKRAKE |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P27348 | S45 | Sugiyama | YWHAQ | CMKAVtEQGAELsNEERNLLsVAyKNVVGGRRSAWRVIsSI |
| P29692 | S65 | Sugiyama | EEF1D EF1D | VILRDIARARENIQKsLAGssGPGAssGtsGDHGELVVRIA |
| P29692 | S74 | Sugiyama | EEF1D EF1D | RENIQKsLAGssGPGAssGtsGDHGELVVRIAsLEVENQsL |
| P30086 | S52 | Sugiyama | PEBP1 PBP PEBP | AAVDELGKVLtPtQVKNRPtsIsWDGLDsGKLytLVLtDPD |
| P31946 | S47 | Sugiyama | YWHAB | AMKAVtEQGHELsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P31947 | S45 | Sugiyama | SFN HME1 | FMKGAVEKGEELsCEERNLLsVAyKNVVGGQRAAWRVLSsI |
| P31949 | T33 | Sugiyama | S100A11 MLN70 S100C | CIESLIAVFQKYAGKDGyNytLsKtEFLsFMNTELAAFTKN |
| P33316 | S120 | Sugiyama | DUT | PsKRARPAEVGGMQLRFARLsEHAtAPTRGsARAAGYDLYS |
| P33778 | S37 | Sugiyama | H2BC3 H2BFF HIST1H2BB | KAITKAQKKDGKKRKRsRKEsysIyVyKVLKQVHPDTGISS |
| P34932 | S76 | Sugiyama | HSPA4 APG2 HSPH2 | VISNAKNTVQGFKRFHGRAFsDPFVEAEKSNLAYDIVQLPT |
| P35269 | T41 | Sugiyama | GTF2F1 RAP74 | NTTKKyNIMAFNAADKVNFAtWNQARLERDLSNKKIyQEEE |
| P36578 | T84 | Sugiyama | RPL4 RPL1 | AEsWGtGRAVARIPRVRGGGtHRsGQGAFGNMCRGGRMFAP |
| P37108 | Y27 | Sugiyama | SRP14 | EQFLtELTRLFQKCRTSGsVyItLKKYDGRTKPIPKKGtVE |
| P37802 | S163 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | LFsGDPNWFPKKSKENPRNFsDNQLQEGKNVIGLQMGtNRG |
| P37802 | S185 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | NQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL______ |
| P38646 | S89 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | VMEGKQAKVLENAEGARttPsVVAFtADGERLVGMPAKRQA |
| P38936 | S146 | SIGNOR | CDKN1A CAP20 CDKN1 CIP1 MDA6 PIC1 SDI1 WAF1 | QAEGsPGGPGDSQGRKRRQtsMTDFYHsKRRLIFSKRKP__ |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P43243 | S188 | Sugiyama | MATR3 KIAA0723 | EPPyRVPRDDWEEKRHFRRDsFDDRGPsLNPVLDyDHGsRs |
| P43487 | S60 | Sugiyama | RANBP1 | TLEEDEEELFKMRAKLFRFAsENDLPEWKERGTGDVKLLKH |
| P46777 | S224 | Sugiyama | RPL5 MSTP030 | VADyMRyLMEEDEDAyKKQFsQyIKNsVtPDMMEEMyKKAH |
| P46783 | S146 | Sugiyama | RPS10 | TYRRSAVPPGADKKAEAGAGsAtEFQFRGGFGRGRGQPPQ_ |
| P46937 | S109 | SIGNOR|EPSD|PSP|Sugiyama | YAP1 YAP65 | RKLPDsFFKPPEPKsHsRQAstDAGtAGALtPQHVRAHssP |
| P46937 | S127 | SIGNOR|EPSD|PSP | YAP1 YAP65 | QAstDAGtAGALtPQHVRAHssPAsLQLGAVsPGtLtPtGV |
| P46937 | S164 | EPSD|PSP | YAP1 YAP65 | PtGVVsGPAAtPTAQHLRQssFEIPDDVPLPAGWEMAKTSS |
| P46937 | S61 | EPSD|PSP | YAP1 YAP65 | tQAAPQAPPAGHQIVHVRGDsEtDLEALFNAVMNPKtANVP |
| P47712 | S727 | Sugiyama | PLA2G4A CPLA2 PLA2G4 | VIKEAMVESIEyRRQNPsRCsVsLsNVEARRFFNKEFLSKP |
| P49321 | S659 | Sugiyama | NASP | IEELKELLPEIREKIEDAKEsQRsGNVAELALKATLVEsst |
| P49321 | S662 | Sugiyama | NASP | LKELLPEIREKIEDAKEsQRsGNVAELALKATLVEsstsGF |
| P50990 | S23 | Sugiyama | CCT8 C21orf112 CCTQ KIAA0002 | LHVPKAPGFAQMLKEGAKHFsGLEEAVyRNIQACKELAQTT |
| P51116 | S601 | Sugiyama | FXR2 FMR1L2 | RPQRRNRSRRRRNRGNRtDGsIsGDRQPVtVADyIsRAEsQ |
| P51116 | T598 | Sugiyama | FXR2 FMR1L2 | DESRPQRRNRSRRRRNRGNRtDGsIsGDRQPVtVADyIsRA |
| P51532 | S1382 | Sugiyama | SMARCA4 BAF190A BRG1 SNF2B SNF2L4 | EEEKMFGRGSRHRKEVDYsDsLTEKQWLKAIEEGtLEEIEE |
| P53396 | S455 | Sugiyama | ACLY | ANFLLNAsGststPAPsRtAsFsEsRADEVAPAKKAKPAMP |
| P53396 | S459 | Sugiyama | ACLY | LNAsGststPAPsRtAsFsEsRADEVAPAKKAKPAMPQDsV |
| P57053 | S37 | Sugiyama | H2BC12L H2BFS H2BS1 | KAVTKAQKKDGRKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| P57053 | S39 | Sugiyama | H2BC12L H2BFS H2BS1 | VTKAQKKDGRKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| P58876 | S37 | Sugiyama | H2BC5 H2BFB HIRIP2 HIST1H2BD | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| P58876 | S39 | Sugiyama | H2BC5 H2BFB HIRIP2 HIST1H2BD | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| P60174 | S212 | Sugiyama | TPI1 TPI | WLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLV |
| P60709 | S323 | Sugiyama | ACTB | ttMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGG |
| P60709 | S52 | Sugiyama | ACTB | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P60709 | T324 | Sugiyama | ACTB | tMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGGs |
| P60709 | Y53 | Sugiyama | ACTB | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIEH |
| P61221 | Y594 | Sugiyama | ABCE1 RLI RNASEL1 RNASELI RNS4I OK/SW-cl.40 | RPRINKLNsIKDVEQKKsGNyFFLDD_______________ |
| P61247 | S236 | Sugiyama | RPS3A FTE1 MFTL | KMLKKPKFELGKLMELHGEGsssGKAtGDEtGAKVERADGy |
| P61247 | S238 | Sugiyama | RPS3A FTE1 MFTL | LKKPKFELGKLMELHGEGsssGKAtGDEtGAKVERADGyEP |
| P61313 | S100 | Sugiyama | RPL15 EC45 TCBAP0781 | tyGKPVHHGVNQLKFARsLQsVAEERAGRHCGALRVLNsyW |
| P61978 | S75 | Sugiyama | HNRNPK HNRPK | GAVIGKGGKNIKALRtDyNAsVsVPDssGPERILsISADIE |
| P61978 | T70 | Sugiyama | HNRNPK HNRPK | QSKNAGAVIGKGGKNIKALRtDyNAsVsVPDssGPERILsI |
| P61981 | S46 | Sugiyama | YWHAG | AMKNVtELNEPLsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | S46 | Sugiyama | YWHAE | SMKKVAGMDVELTVEERNLLsVAyKNVIGARRASWRIIssI |
| P62263 | S137 | Sugiyama | RPS14 PRO2640 | RALARSGMKIGRIEDVtPIPsDstRRKGGRRGRRL______ |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62277 | S12 | Sugiyama | RPS13 | _________MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDD |
| P62424 | T84 | Sugiyama | RPL7A SURF-3 SURF3 | QRQRAILyKRLKVPPAINQFtQALDRQTAtQLLKLAHKYRP |
| P62736 | S325 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P62736 | S54 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P62736 | T326 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P62736 | Y55 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P62807 | S37 | Sugiyama | H2BC4 H2BFL HIST1H2BC; H2BC6 H2BFH HIST1H2BE; H2BC7 H2BFG HIST1H2BF; H2BC8 H2BFA HIST1H2BG; H2BC10 H2BFK HIST1H2BI | KAVTKAQKKDGKKRKRsRKEsysVyVyKVLKQVHPDTGIss |
| P62807 | S39 | Sugiyama | H2BC4 H2BFL HIST1H2BC; H2BC6 H2BFH HIST1H2BE; H2BC7 H2BFG HIST1H2BF; H2BC8 H2BFA HIST1H2BG; H2BC10 H2BFK HIST1H2BI | VTKAQKKDGKKRKRsRKEsysVyVyKVLKQVHPDTGIssKA |
| P62899 | S15 | Sugiyama | RPL31 | ______MAPAKKGGEKKKGRsAINEVVtREytINIHKRIHG |
| P62917 | S130 | Sugiyama | RPL8 | GTIVCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKL |
| P63104 | S45 | Sugiyama | YWHAZ | CMKsVtEQGAELsNEERNLLsVAyKNVVGARRssWRVVssI |
| P63104 | T30 | Sugiyama | YWHAZ | AKLAEQAERyDDMAACMKsVtEQGAELsNEERNLLsVAyKN |
| P63173 | T14 | Sugiyama | RPL38 | _______MPRKIEEIKDFLLtARRKDAKSVKIKKNKDNVKF |
| P63261 | S323 | Sugiyama | ACTG1 ACTG | ttMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGG |
| P63261 | S52 | Sugiyama | ACTG1 ACTG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P63261 | T324 | Sugiyama | ACTG1 ACTG | tMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGGs |
| P63261 | Y53 | Sugiyama | ACTG1 ACTG | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIEH |
| P63267 | S324 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P63267 | S53 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P63267 | T325 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P63267 | Y54 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P67809 | S209 | Sugiyama | YBX1 NSEP1 YB1 | RRRRFPPyyMRRPYGRRPQysNPPVQGEVMEGADNQGAGEQ |
| P68032 | S325 | Sugiyama | ACTC1 ACTC | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P68032 | S54 | Sugiyama | ACTC1 ACTC | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68032 | T326 | Sugiyama | ACTC1 ACTC | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P68032 | Y55 | Sugiyama | ACTC1 ACTC | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P68133 | S325 | Sugiyama | ACTA1 ACTA | TTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P68133 | S54 | Sugiyama | ACTA1 ACTA | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68133 | T326 | Sugiyama | ACTA1 ACTA | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P68133 | Y55 | Sugiyama | ACTA1 ACTA | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P78345 | S253 | Sugiyama | RPP38 | DtsFEDLsKPKRKLADGRQAsVtLQPLKIKKLIPNPNKIRK |
| Q00839 | Y260 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | GDKKRGVKRPREDHGRGyFEyIEENKysRAKsPQPPVEEED |
| Q02241 | S716 | EPSD|PSP | KIF23 KNSL5 MKLP1 | AQISNGQQLMSQPQLHRRsNsCssISVASCISEWEQKIPTy |
| Q02241 | S814 | EPSD|PSP | KIF23 KNSL5 MKLP1 | LLFQPDQNAPPIRLRHRRsRsAGDRWVDHKPASNMQTETVM |
| Q04917 | S46 | Sugiyama | YWHAH YWHA1 | AMKAVtELNEPLsNEDRNLLsVAyKNVVGARRSsWRVIsSI |
| Q07020 | T136 | Sugiyama | RPL18 | AGGKILtFDQLALDsPKGCGtVLLsGPRKGREVYRHFGKAP |
| Q07020 | T85 | Sugiyama | RPL18 | RMIRKMKLPGRENKtAVVVGtItDDVRVQEVPKLKVCALRV |
| Q13247 | S297 | Sugiyama | SRSF6 SFRS6 SRP55 | RSRSPKENGKGDIKsKSRsRsQsRsNsPLPVPPsKARsVsP |
| Q13442 | S19 | Sugiyama | PDAP1 HASPP28 | __MPKGGRKGGHKGRARQytsPEEIDAQLQAEKQKAREEEE |
| Q13561 | Y81 | Sugiyama | DCTN2 DCTN50 | RVGTKGLDFsDRIGKTKRtGyEsGEyEMLGEGLGVKETPQQ |
| Q14568 | S53 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | IINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKLDSG |
| Q14568 | Y283 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | sDEEEEKKDGDKKKKKTKEKyIDQEELNKTKPIWTRNPDDI |
| Q14847 | S61 | Sugiyama | LASP1 MLN50 | MKNYKGYEKKPYCNAHyPKQsFtMVADtPENLRLKQQSELQ |
| Q14978 | S686 | Sugiyama | NOLC1 KIAA0035 NS5ATP13 | KGKSFRHEKTKKKRGsYRGGsIsVQVNsIKFDsE_______ |
| Q15208 | S281 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | STK38 NDR1 | NMNsKRKAEtWKRNRRQLAFstVGtPDYIAPEVFMQTGYNK |
| Q15208 | S32 | Sugiyama | STK38 NDR1 | MSNHTKERVTMTKVTLENFysNLIAQHEEREMRQKKLEKVM |
| Q15208 | S398 | Sugiyama | STK38 NDR1 | SNSFFEGVDWEHIRERPAAIsIEIKSIDDtSNFDEFPESDI |
| Q15208 | S459 | Sugiyama | STK38 NDR1 | VFINytYKRFEGLtARGAIPsYMKAAK______________ |
| Q15208 | T444 | SIGNOR|iPTMNet|EPSD|PSP|Sugiyama | STK38 NDR1 | ATSNHPETDYKNKDWVFINytYKRFEGLtARGAIPsYMKAA |
| Q15208 | T452 | Sugiyama | STK38 NDR1 | DYKNKDWVFINytYKRFEGLtARGAIPsYMKAAK_______ |
| Q15208 | T74 | SIGNOR|iPTMNet|EPSD|Sugiyama | STK38 NDR1 | EEGLKDEEKRLRRSAHARKEtEFLRLKRTRLGLEDFEsLKV |
| Q15208 | Y443 | Sugiyama | STK38 NDR1 | VATSNHPETDYKNKDWVFINytYKRFEGLtARGAIPsYMKA |
| Q15293 | Y115 | Sugiyama | RCN1 RCN | GDGFVttEELKtWIKRVQKRyIFDNVAKVWKDYDRDKDDKI |
| Q16658 | T239 | Sugiyama | FSCN1 FAN1 HSN SNL | GKVAFRDCEGRyLAPsGPsGtLKAGKATKVGKDELFALEQs |
| Q16778 | S37 | Sugiyama | H2BC21 H2BFQ HIST2H2BE | KAVTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGIss |
| Q2M2I8 | S637 | SIGNOR | AAK1 KIAA1048 | GsLtPPssPKTQRAGHRRILsDVtHsAVFGVPAsKstQLLQ |
| Q58FF8 | Y198 | Sugiyama | HSP90AB2P HSP90BB | DEEDDsGKDKKKKTKKIKEKyIDQEELNKTKPIWTRNTEDI |
| Q5QNW6 | S37 | Sugiyama | H2BC18 HIST2H2BF | KAVTKVQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q5QNW6 | S39 | Sugiyama | H2BC18 HIST2H2BF | VTKVQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q5T5C0 | S692 | Sugiyama | STXBP5 LLGL3 | YGSNDPYRREPRSPRKsRQPsGAGLCDIsEGtVVPEDRCKS |
| Q6DN03 | S37 | Sugiyama | H2BC20P HIST2H2BC | KAVTKAQKKDGKKRKRSRKEsysIyVyKVLKRVHPDTGIWC |
| Q6DRA6 | S37 | Sugiyama | H2BC19P HIST2H2BD | KAVTKAQKKDGKKRKRSRKEsysIyVyKVLKRVHPDTGIWC |
| Q6P6C2 | S361 | Sugiyama | ALKBH5 ABH5 OFOXD1 | EMDKEENRRSVLLPTHRRRGsFssENYWRKsyEssEDCsEA |
| Q6ZMR3 | S161 | Sugiyama | LDHAL6A LDHL2 | DILTYVAWKLSGFPKNRVIGsGCNLDsARFRYFIGQRLGIH |
| Q7Z417 | S655 | Sugiyama | NUFIP2 KIAA1321 PIG1 | LGsAKEQRYQRGLERNDsWGsFDLRAAIVYHTKEMEsIWNL |
| Q7Z4V5 | S454 | Sugiyama | HDGFL2 HDGF2 HDGFRP2 HRP2 UNQ785/PRO1604 | VRPEEKQQAKPVKVERTRKRsEGFsMDRKVEKKKEPSVEEK |
| Q86VQ1 | S223 | Sugiyama | GLCCI1 | QTPsCWAEEGAEKRSHQRsAsWGsADQLKEQIAKLRQQLQR |
| Q8N257 | S37 | Sugiyama | H2BC26 H2BU1 HIST3H2BB | KAVTKAQKKDGKKRKRGRKEsysIyVyKVLKQVHPDTGIss |
| Q93079 | S37 | Sugiyama | H2BC9 H2BFJ HIST1H2BH | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q93079 | S39 | Sugiyama | H2BC9 H2BFJ HIST1H2BH | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q96QF0 | S288 | SIGNOR|EPSD|PSP | RAB3IP RABIN8 | tQEPLPGGKTPFKKGHTRNKstssAMsGsHQDLSVIQPIVK |
| Q96RD6 | S514 | SIGNOR | PANX2 | GPAPAPAPPPAPDKKHARHFsLDVHPYILGTKKAKAEAVPA |
| Q99877 | S37 | Sugiyama | H2BC15 H2BFD HIST1H2BN | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q99877 | S39 | Sugiyama | H2BC15 H2BFD HIST1H2BN | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q99879 | S37 | Sugiyama | H2BC14 H2BFE HIST1H2BM | KAINKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q99879 | S39 | Sugiyama | H2BC14 H2BFE HIST1H2BM | INKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q99880 | S37 | Sugiyama | H2BC13 H2BFC HIST1H2BL | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q99880 | S39 | Sugiyama | H2BC13 H2BFC HIST1H2BL | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q9BTU6 | S462 | Sugiyama | PI4K2A | HLVQMPPVIVETARSHQRsssEsyTQsFQSRKPFFSWW___ |
| Q9BXF6 | S307 | SIGNOR | RAB11FIP5 GAF1 KIAA0857 RIP11 | TEGGRDsAQsPKLFTHKRtYsDEANQMRVAPPRALLDLQGH |
| Q9GZL7 | S206 | Sugiyama | WDR12 | RGHAGSVDSIAVDGSGTKFCsGSWDKMLKIWStVPtDEEDE |
| Q9H1K0 | S548 | Sugiyama | RBSN ZFYVE20 | RELEREREQFRVASLHTRTRsLDFREIGPFQLEPSREPRTH |
| Q9NQ39 | S157 | Sugiyama | RPS10P5 RPS10L | TYRRCSVPPGADKKAEAGAGsAtEFQFRGRCGRGRGQPPQ_ |
| Q9NTI5 | S1257 | Sugiyama | PDS5B APRIN AS3 KIAA0979 | LVQEQKPKGSQRSRKRGHtAsEsDEQQWPEEKRLKEDILEN |
| Q9UBF8 | S277 | SIGNOR | PI4KB PIK4CB | LsPAPDtGLsPsKRTHQRsKsDAtAsISLSSNLKRTAsNPK |
| Q9UGV2 | S331 | Sugiyama | NDRG3 | QGMGYIPSASMTRLARsRtHstsssLGsGEsPFsRsVtsNQ |
| Q9UI15 | S185 | Sugiyama | TAGLN3 NP25 | EQLRQGQNVIGLQMGSNKGAsQAGMtGyGMPRQIM______ |
| Q9UKX7 | S52 | Sugiyama | NUP50 NPAP60L PRO1146 | EEVLKNRAIKKAKRRNVGFEsDtGGAFKGFKGLVVPSGGGR |
| Q9UPQ0 | S201 | Sugiyama | LIMCH1 KIAA1102 | DCWDsERsDsLsPPRHGRDDsFDsLDsFGsRsRQtPsPDVV |
| Q9UQ35 | S2692 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | ERRSRSPRKPIDsLRDsRsLsysPVERRRPsPQPsPRDQQS |
| Q9UQE7 | S961 | Sugiyama | SMC3 BAM BMH CSPG6 SMC3L1 | KKIRELGSLPQEAFEKYQtLsLKQLFRKLEQCNTELKKYSH |
| Q9UQE7 | T959 | Sugiyama | SMC3 BAM BMH CSPG6 SMC3L1 | CMKKIRELGSLPQEAFEKYQtLsLKQLFRKLEQCNTELKKY |
| Q9Y2H1 | T75 | Sugiyama | STK38L KIAA0965 NDR2 | EEGLADEEKKLRRSQHARKEtEFLRLKRTRLGLDDFESLKV |
| Q9Y5M8 | S257 | Sugiyama | SRPRB PSEC0230 | LPLKVEFLECSAKGGRGDVGsADIQDLEKWLAKIA______ |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Chromatin modifying enzymes | R-HSA-3247509 | 5.936080e-07 | 6.227 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 1.694982e-06 | 5.771 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 5.157315e-06 | 5.288 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.543131e-05 | 4.812 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.792156e-05 | 4.747 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 3.536869e-05 | 4.451 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 3.645184e-05 | 4.438 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 4.342138e-05 | 4.362 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 4.459275e-05 | 4.351 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 5.530779e-05 | 4.257 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 5.693850e-05 | 4.245 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 7.704724e-05 | 4.113 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 8.973879e-05 | 4.047 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.002622e-04 | 3.999 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 1.777902e-04 | 3.750 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.961270e-04 | 3.707 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.084426e-04 | 3.681 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 2.324438e-04 | 3.634 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.305170e-04 | 3.637 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.421381e-04 | 3.616 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.247476e-04 | 3.488 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 3.727502e-04 | 3.429 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 3.822708e-04 | 3.418 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 4.837472e-04 | 3.315 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 5.708942e-04 | 3.243 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 5.607490e-04 | 3.251 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 1.125614e-03 | 2.949 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 1.125614e-03 | 2.949 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 1.179661e-03 | 2.928 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 1.198151e-03 | 2.921 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 1.364318e-03 | 2.865 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 1.780918e-03 | 2.749 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.809263e-03 | 2.742 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.769973e-03 | 2.752 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 2.214558e-03 | 2.655 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 2.412196e-03 | 2.618 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 2.821066e-03 | 2.550 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 2.829821e-03 | 2.548 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 2.967688e-03 | 2.528 | 1 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 3.215896e-03 | 2.493 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 3.296596e-03 | 2.482 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 3.645351e-03 | 2.438 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 3.685537e-03 | 2.433 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 3.570680e-03 | 2.447 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 3.925913e-03 | 2.406 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 4.034701e-03 | 2.394 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 4.326992e-03 | 2.364 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 4.572039e-03 | 2.340 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 4.598837e-03 | 2.337 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 4.984630e-03 | 2.302 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 5.266550e-03 | 2.278 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 5.402887e-03 | 2.267 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 5.402887e-03 | 2.267 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 5.755180e-03 | 2.240 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 7.191119e-03 | 2.143 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 6.810127e-03 | 2.167 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 7.318458e-03 | 2.136 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 7.073876e-03 | 2.150 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 7.091192e-03 | 2.149 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 9.156032e-03 | 2.038 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 9.156032e-03 | 2.038 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 8.935068e-03 | 2.049 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 9.166284e-03 | 2.038 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 9.421060e-03 | 2.026 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 9.421060e-03 | 2.026 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 1.195000e-02 | 1.923 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.182193e-02 | 1.927 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 1.353646e-02 | 1.868 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 1.429357e-02 | 1.845 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.388555e-02 | 1.857 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 1.474139e-02 | 1.831 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 1.547653e-02 | 1.810 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.547654e-02 | 1.810 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 1.587017e-02 | 1.799 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.807530e-02 | 1.743 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 1.828604e-02 | 1.738 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 1.828604e-02 | 1.738 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.807530e-02 | 1.743 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 1.745340e-02 | 1.758 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.889963e-02 | 1.724 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.894221e-02 | 1.723 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.907561e-02 | 1.720 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.907561e-02 | 1.720 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 2.032961e-02 | 1.692 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 1.949688e-02 | 1.710 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.044485e-02 | 1.689 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 2.065056e-02 | 1.685 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.258244e-02 | 1.646 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.258244e-02 | 1.646 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.258244e-02 | 1.646 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.258244e-02 | 1.646 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.258244e-02 | 1.646 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 2.205564e-02 | 1.656 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.274591e-02 | 1.643 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 2.452000e-02 | 1.610 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 2.452000e-02 | 1.610 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 2.452000e-02 | 1.610 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 2.452000e-02 | 1.610 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 2.378393e-02 | 1.624 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.434233e-02 | 1.614 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.434233e-02 | 1.614 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.523670e-02 | 1.598 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 2.680929e-02 | 1.572 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 2.680929e-02 | 1.572 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 2.732576e-02 | 1.563 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.795584e-02 | 1.554 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 2.779740e-02 | 1.556 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 2.854891e-02 | 1.544 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 2.915300e-02 | 1.535 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 2.925765e-02 | 1.534 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 2.949732e-02 | 1.530 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 3.264769e-02 | 1.486 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 3.080518e-02 | 1.511 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 3.105690e-02 | 1.508 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 3.264769e-02 | 1.486 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 3.253689e-02 | 1.488 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 3.228535e-02 | 1.491 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 3.304517e-02 | 1.481 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 3.363926e-02 | 1.473 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 3.433863e-02 | 1.464 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 3.514053e-02 | 1.454 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 3.840356e-02 | 1.416 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 3.576762e-02 | 1.447 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 3.583369e-02 | 1.446 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 3.872819e-02 | 1.412 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 3.872819e-02 | 1.412 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 3.884952e-02 | 1.411 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 3.908620e-02 | 1.408 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 3.922414e-02 | 1.406 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 3.924727e-02 | 1.406 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 3.924727e-02 | 1.406 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 4.716293e-02 | 1.326 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 4.806159e-02 | 1.318 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 4.476051e-02 | 1.349 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 4.507082e-02 | 1.346 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 4.806159e-02 | 1.318 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 4.771540e-02 | 1.321 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 4.554910e-02 | 1.342 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 4.806159e-02 | 1.318 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 5.069330e-02 | 1.295 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 5.095039e-02 | 1.293 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 5.164974e-02 | 1.287 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 5.164974e-02 | 1.287 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 5.167384e-02 | 1.287 | 0 | 0 |
| Kinesins | R-HSA-983189 | 5.406125e-02 | 1.267 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 6.565605e-02 | 1.183 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 6.565605e-02 | 1.183 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 6.435281e-02 | 1.191 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 6.051957e-02 | 1.218 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 5.884352e-02 | 1.230 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 6.639701e-02 | 1.178 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 6.080268e-02 | 1.216 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 6.212231e-02 | 1.207 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 6.403742e-02 | 1.194 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 6.456637e-02 | 1.190 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 5.487005e-02 | 1.261 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 6.565605e-02 | 1.183 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 5.884352e-02 | 1.230 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 6.639701e-02 | 1.178 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 6.332535e-02 | 1.198 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 6.332535e-02 | 1.198 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 6.435281e-02 | 1.191 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 6.435281e-02 | 1.191 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 6.051957e-02 | 1.218 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 5.884352e-02 | 1.230 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 6.661064e-02 | 1.176 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 6.733021e-02 | 1.172 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 6.787835e-02 | 1.168 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 7.003517e-02 | 1.155 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 7.073483e-02 | 1.150 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 7.085663e-02 | 1.150 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.083134e-01 | 0.965 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.083134e-01 | 0.965 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.083134e-01 | 0.965 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.083134e-01 | 0.965 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.083134e-01 | 0.965 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.083134e-01 | 0.965 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.083134e-01 | 0.965 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.083134e-01 | 0.965 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.083134e-01 | 0.965 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 7.788512e-02 | 1.109 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 7.788512e-02 | 1.109 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 7.788512e-02 | 1.109 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.049007e-01 | 0.688 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 2.049007e-01 | 0.688 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 2.049007e-01 | 0.688 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.049007e-01 | 0.688 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 1.131316e-01 | 0.946 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 1.131316e-01 | 0.946 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 8.617867e-02 | 1.065 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.515630e-01 | 0.819 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.515630e-01 | 0.819 | 0 | 0 |
| PI and PC transport between ER and Golgi membranes | R-HSA-1483196 | 2.910307e-01 | 0.536 | 0 | 0 |
| NFG and proNGF binds to p75NTR | R-HSA-205017 | 2.910307e-01 | 0.536 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 2.910307e-01 | 0.536 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 2.910307e-01 | 0.536 | 0 | 0 |
| Intestinal infectious diseases | R-HSA-8942233 | 2.910307e-01 | 0.536 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 2.910307e-01 | 0.536 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 2.910307e-01 | 0.536 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 2.910307e-01 | 0.536 | 0 | 0 |
| MyD88 deficiency (TLR5) | R-HSA-5602680 | 2.910307e-01 | 0.536 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 2.910307e-01 | 0.536 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 2.910307e-01 | 0.536 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 2.910307e-01 | 0.536 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 1.090405e-01 | 0.962 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 1.920767e-01 | 0.717 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 1.920767e-01 | 0.717 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.920767e-01 | 0.717 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.339473e-01 | 0.873 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 1.339473e-01 | 0.873 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 1.339473e-01 | 0.873 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 1.339473e-01 | 0.873 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 9.604585e-02 | 1.018 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 9.604585e-02 | 1.018 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 1.141690e-01 | 0.942 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 1.605919e-01 | 0.794 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.605919e-01 | 0.794 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 2.337714e-01 | 0.631 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 2.337714e-01 | 0.631 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 3.678351e-01 | 0.434 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 3.678351e-01 | 0.434 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 3.678351e-01 | 0.434 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 3.678351e-01 | 0.434 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 3.678351e-01 | 0.434 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 3.678351e-01 | 0.434 | 0 | 0 |
| Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum) | R-HSA-5655799 | 3.678351e-01 | 0.434 | 0 | 0 |
| Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages) | R-HSA-5619049 | 3.678351e-01 | 0.434 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 3.678351e-01 | 0.434 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 3.678351e-01 | 0.434 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 3.678351e-01 | 0.434 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 3.678351e-01 | 0.434 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 3.678351e-01 | 0.434 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 3.678351e-01 | 0.434 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 3.678351e-01 | 0.434 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 3.678351e-01 | 0.434 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 3.678351e-01 | 0.434 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 3.678351e-01 | 0.434 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 9.666507e-02 | 1.015 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 9.666507e-02 | 1.015 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 1.336655e-01 | 0.874 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.886660e-01 | 0.724 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 1.886660e-01 | 0.724 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.116457e-01 | 0.952 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 2.759164e-01 | 0.559 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 2.759164e-01 | 0.559 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 2.759164e-01 | 0.559 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 7.885090e-02 | 1.103 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 2.178688e-01 | 0.662 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 2.178688e-01 | 0.662 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 1.762645e-01 | 0.754 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.762645e-01 | 0.754 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 1.446758e-01 | 0.840 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 1.000659e-01 | 1.000 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.342576e-01 | 0.872 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 1.625926e-01 | 0.789 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.625926e-01 | 0.789 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 1.625926e-01 | 0.789 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 1.625926e-01 | 0.789 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 1.625926e-01 | 0.789 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.990895e-01 | 0.701 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 2.479130e-01 | 0.606 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 2.479130e-01 | 0.606 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 3.179255e-01 | 0.498 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 3.179255e-01 | 0.498 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 3.179255e-01 | 0.498 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 3.179255e-01 | 0.498 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 3.179255e-01 | 0.498 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 3.179255e-01 | 0.498 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 3.179255e-01 | 0.498 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 3.179255e-01 | 0.498 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 4.363231e-01 | 0.360 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.363231e-01 | 0.360 | 0 | 0 |
| Defective ABCA1 causes TGD | R-HSA-5682113 | 4.363231e-01 | 0.360 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.363231e-01 | 0.360 | 0 | 0 |
| Defective ABCA3 causes SMDP3 | R-HSA-5683678 | 4.363231e-01 | 0.360 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 4.363231e-01 | 0.360 | 0 | 0 |
| Defective ABCA3 causes SMDP3 | R-HSA-5688399 | 4.363231e-01 | 0.360 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 4.363231e-01 | 0.360 | 0 | 0 |
| Defective GCLC causes HAGGSD | R-HSA-5578999 | 4.363231e-01 | 0.360 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 1.240827e-01 | 0.906 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 1.493828e-01 | 0.826 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 1.493828e-01 | 0.826 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 2.227395e-01 | 0.652 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.785292e-01 | 0.555 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 2.785292e-01 | 0.555 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.785292e-01 | 0.555 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.785292e-01 | 0.555 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.785292e-01 | 0.555 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.785292e-01 | 0.555 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 1.258209e-01 | 0.900 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 2.008475e-01 | 0.697 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 8.971050e-02 | 1.047 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 1.817591e-01 | 0.741 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 1.817591e-01 | 0.741 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 3.593337e-01 | 0.445 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 9.761075e-02 | 1.011 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 9.761075e-02 | 1.011 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 1.989086e-01 | 0.701 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 1.989086e-01 | 0.701 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 3.094689e-01 | 0.509 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 3.094689e-01 | 0.509 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 3.094689e-01 | 0.509 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.798230e-01 | 0.745 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 2.719376e-01 | 0.566 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 2.166257e-01 | 0.664 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 2.166257e-01 | 0.664 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 1.951852e-01 | 0.710 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 1.951852e-01 | 0.710 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.766150e-01 | 0.753 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.766150e-01 | 0.753 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.972044e-01 | 0.527 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 3.405060e-01 | 0.468 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 3.405060e-01 | 0.468 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 3.997786e-01 | 0.398 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 3.997786e-01 | 0.398 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 3.997786e-01 | 0.398 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 3.997786e-01 | 0.398 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 4.973948e-01 | 0.303 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 4.973948e-01 | 0.303 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 4.973948e-01 | 0.303 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 4.973948e-01 | 0.303 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 4.973948e-01 | 0.303 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 4.973948e-01 | 0.303 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 4.973948e-01 | 0.303 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 4.973948e-01 | 0.303 | 0 | 0 |
| Defective CP causes aceruloplasminemia (ACERULOP) | R-HSA-5619060 | 4.973948e-01 | 0.303 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.278266e-01 | 0.893 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 2.273602e-01 | 0.643 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.494110e-01 | 0.826 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 2.846589e-01 | 0.546 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.454404e-01 | 0.837 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 1.187429e-01 | 0.925 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.035061e-01 | 0.985 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 3.714374e-01 | 0.430 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 3.714374e-01 | 0.430 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 3.714374e-01 | 0.430 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 1.642838e-01 | 0.784 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.977481e-01 | 0.704 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.977481e-01 | 0.704 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 2.919878e-01 | 0.535 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 4.389830e-01 | 0.358 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 4.389830e-01 | 0.358 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 4.389830e-01 | 0.358 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.575582e-01 | 0.803 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 2.786119e-01 | 0.555 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 2.786119e-01 | 0.555 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 3.288147e-01 | 0.483 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.660521e-01 | 0.780 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 1.550782e-01 | 0.809 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 4.020834e-01 | 0.396 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 4.020834e-01 | 0.396 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 2.963150e-01 | 0.528 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 2.963150e-01 | 0.528 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 2.963150e-01 | 0.528 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 3.741041e-01 | 0.427 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 2.697288e-01 | 0.569 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.580184e-01 | 0.588 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 3.315154e-01 | 0.479 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 3.315154e-01 | 0.479 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 3.315154e-01 | 0.479 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 3.142521e-01 | 0.503 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 2.131936e-01 | 0.671 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 3.000903e-01 | 0.523 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 3.323778e-01 | 0.478 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 3.735678e-01 | 0.428 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 3.997100e-01 | 0.398 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 3.997100e-01 | 0.398 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 4.322869e-01 | 0.364 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 4.767412e-01 | 0.322 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 4.767412e-01 | 0.322 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 4.767412e-01 | 0.322 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 4.767412e-01 | 0.322 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 5.518528e-01 | 0.258 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 5.518528e-01 | 0.258 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 5.518528e-01 | 0.258 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 2.515054e-01 | 0.599 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 2.418815e-01 | 0.616 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 3.959728e-01 | 0.402 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 2.003704e-01 | 0.698 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 4.619125e-01 | 0.335 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 3.628838e-01 | 0.440 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 3.628838e-01 | 0.440 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 5.129064e-01 | 0.290 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 4.404843e-01 | 0.356 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 4.908454e-01 | 0.309 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 4.908454e-01 | 0.309 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 4.243006e-01 | 0.372 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 4.048904e-01 | 0.393 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 4.518808e-01 | 0.345 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 4.076267e-01 | 0.390 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 4.841775e-01 | 0.315 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 5.189901e-01 | 0.285 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 5.189901e-01 | 0.285 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 5.473806e-01 | 0.262 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 5.473806e-01 | 0.262 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 5.473806e-01 | 0.262 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 5.473806e-01 | 0.262 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 5.473806e-01 | 0.262 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 5.473806e-01 | 0.262 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 6.004131e-01 | 0.222 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 6.004131e-01 | 0.222 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 6.004131e-01 | 0.222 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 6.004131e-01 | 0.222 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 6.004131e-01 | 0.222 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 6.004131e-01 | 0.222 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 6.004131e-01 | 0.222 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 6.004131e-01 | 0.222 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 6.004131e-01 | 0.222 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 4.350735e-01 | 0.361 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 5.232003e-01 | 0.281 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 5.462687e-01 | 0.263 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.061263e-01 | 0.296 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 5.464746e-01 | 0.262 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 5.464746e-01 | 0.262 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 5.464746e-01 | 0.262 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 5.726197e-01 | 0.242 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 5.691429e-01 | 0.245 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 5.691429e-01 | 0.245 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 5.674465e-01 | 0.246 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 5.674465e-01 | 0.246 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 5.666926e-01 | 0.247 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 5.666926e-01 | 0.247 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 5.911654e-01 | 0.228 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 5.911654e-01 | 0.228 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 5.979961e-01 | 0.223 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 6.110560e-01 | 0.214 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 6.110560e-01 | 0.214 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 6.437141e-01 | 0.191 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 6.437141e-01 | 0.191 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 6.437141e-01 | 0.191 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 6.437141e-01 | 0.191 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 6.051506e-01 | 0.218 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 6.125093e-01 | 0.213 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 6.125093e-01 | 0.213 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 6.223643e-01 | 0.206 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 6.402319e-01 | 0.194 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 6.402319e-01 | 0.194 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 6.402319e-01 | 0.194 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 6.402319e-01 | 0.194 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 6.402319e-01 | 0.194 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 6.432327e-01 | 0.192 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 1.370060e-01 | 0.863 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 1.631456e-01 | 0.787 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 2.273602e-01 | 0.643 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 1.258209e-01 | 0.900 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 2.919878e-01 | 0.535 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 5.357097e-01 | 0.271 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 4.149633e-01 | 0.382 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.532911e-01 | 0.814 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 2.610327e-01 | 0.583 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 2.610327e-01 | 0.583 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 8.480669e-02 | 1.072 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 1.501591e-01 | 0.823 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 6.125093e-01 | 0.213 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 6.023315e-01 | 0.220 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 6.250821e-01 | 0.204 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 6.250821e-01 | 0.204 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 2.610327e-01 | 0.583 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 8.094223e-02 | 1.092 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 2.348524e-01 | 0.629 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 6.125093e-01 | 0.213 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.008475e-01 | 0.697 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 1.550782e-01 | 0.809 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 5.183626e-01 | 0.285 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 2.535288e-01 | 0.596 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 2.919878e-01 | 0.535 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 5.462687e-01 | 0.263 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 5.464746e-01 | 0.262 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 8.278097e-02 | 1.082 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 4.807527e-01 | 0.318 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 4.322869e-01 | 0.364 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 3.155730e-01 | 0.501 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 1.217560e-01 | 0.915 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 1.276701e-01 | 0.894 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.593050e-01 | 0.798 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 1.426673e-01 | 0.846 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 4.327147e-01 | 0.364 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 1.813437e-01 | 0.741 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 2.110446e-01 | 0.676 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.278266e-01 | 0.893 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 5.129064e-01 | 0.290 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 4.993681e-01 | 0.302 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 6.110560e-01 | 0.214 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 5.666926e-01 | 0.247 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 5.182968e-01 | 0.285 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.336655e-01 | 0.874 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 1.798230e-01 | 0.745 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 6.402319e-01 | 0.194 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 3.288147e-01 | 0.483 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 7.530001e-02 | 1.123 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.155305e-01 | 0.937 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 1.649968e-01 | 0.783 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 2.166257e-01 | 0.664 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.144209e-01 | 0.941 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 1.364768e-01 | 0.865 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 2.919878e-01 | 0.535 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 4.389830e-01 | 0.358 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 3.596356e-01 | 0.444 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 4.502621e-01 | 0.347 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.547117e-01 | 0.810 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 1.484382e-01 | 0.828 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.313549e-01 | 0.882 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 4.322869e-01 | 0.364 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 4.908454e-01 | 0.309 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 4.790212e-01 | 0.320 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 4.790212e-01 | 0.320 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 1.649968e-01 | 0.783 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 1.501747e-01 | 0.823 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 9.848167e-02 | 1.007 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 4.020834e-01 | 0.396 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 3.997100e-01 | 0.398 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 4.767412e-01 | 0.322 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 2.624300e-01 | 0.581 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 5.817497e-01 | 0.235 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 6.432327e-01 | 0.192 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 5.194548e-01 | 0.284 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 3.511566e-01 | 0.454 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 3.465829e-01 | 0.460 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 5.670260e-01 | 0.246 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 1.377261e-01 | 0.861 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 5.245744e-01 | 0.280 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 3.227372e-01 | 0.491 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 3.874431e-01 | 0.412 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 3.874431e-01 | 0.412 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.728626e-01 | 0.762 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 1.920767e-01 | 0.717 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 1.339473e-01 | 0.873 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 1.605919e-01 | 0.794 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 2.785292e-01 | 0.555 | 0 | 0 |
| PKA activation | R-HSA-163615 | 2.719376e-01 | 0.566 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 2.163565e-01 | 0.665 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 2.728484e-01 | 0.564 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 5.473806e-01 | 0.262 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 2.522366e-01 | 0.598 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 6.418693e-01 | 0.193 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 3.874431e-01 | 0.412 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 1.593050e-01 | 0.798 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.728626e-01 | 0.762 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 4.993681e-01 | 0.302 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 2.627584e-01 | 0.580 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 2.627584e-01 | 0.580 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 5.066157e-01 | 0.295 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 2.049423e-01 | 0.688 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 2.846589e-01 | 0.546 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 3.959728e-01 | 0.402 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 2.328728e-01 | 0.633 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 5.232003e-01 | 0.281 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 3.198035e-01 | 0.495 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 1.683106e-01 | 0.774 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 4.912171e-01 | 0.309 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 4.951611e-01 | 0.305 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 5.871675e-01 | 0.231 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 4.414157e-01 | 0.355 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 7.505094e-02 | 1.125 | 0 | 0 |
| M Phase | R-HSA-68886 | 8.582776e-02 | 1.066 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 2.549069e-01 | 0.594 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 1.567907e-01 | 0.805 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 1.605919e-01 | 0.794 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 1.336655e-01 | 0.874 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 1.544093e-01 | 0.811 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 3.179255e-01 | 0.498 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 2.227395e-01 | 0.652 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 2.470697e-01 | 0.607 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 3.593337e-01 | 0.445 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 4.322869e-01 | 0.364 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 4.767412e-01 | 0.322 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 4.619125e-01 | 0.335 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 5.129064e-01 | 0.290 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 2.759473e-01 | 0.559 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 4.750338e-01 | 0.323 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 4.624622e-01 | 0.335 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 5.189901e-01 | 0.285 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 5.105384e-01 | 0.292 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 6.402319e-01 | 0.194 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 4.572711e-01 | 0.340 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 1.050708e-01 | 0.979 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 1.668013e-01 | 0.778 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 2.401438e-01 | 0.620 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 5.472522e-01 | 0.262 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 3.714806e-01 | 0.430 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 4.841775e-01 | 0.315 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 4.572711e-01 | 0.340 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 4.924371e-01 | 0.308 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 5.221791e-01 | 0.282 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.402705e-01 | 0.853 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 4.676452e-01 | 0.330 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 2.744580e-01 | 0.562 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 4.653058e-01 | 0.332 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 3.714806e-01 | 0.430 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 3.714806e-01 | 0.430 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 6.162814e-01 | 0.210 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.063538e-01 | 0.973 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 2.846589e-01 | 0.546 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 3.515303e-01 | 0.454 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 4.924371e-01 | 0.308 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.449603e-01 | 0.839 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 5.018200e-01 | 0.299 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 4.526147e-01 | 0.344 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 8.941596e-02 | 1.049 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 5.357097e-01 | 0.271 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 6.241630e-01 | 0.205 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.984683e-01 | 0.702 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 2.785292e-01 | 0.555 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 2.785292e-01 | 0.555 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 2.785292e-01 | 0.555 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 1.649968e-01 | 0.783 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 3.997786e-01 | 0.398 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 4.973948e-01 | 0.303 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.660521e-01 | 0.780 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 5.518528e-01 | 0.258 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 5.518528e-01 | 0.258 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 4.619125e-01 | 0.335 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 3.628838e-01 | 0.440 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.921785e-01 | 0.716 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 2.367419e-01 | 0.626 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 4.912171e-01 | 0.309 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 5.098340e-01 | 0.293 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 5.611748e-01 | 0.251 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 5.008568e-01 | 0.300 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 4.280057e-01 | 0.369 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 5.705755e-01 | 0.244 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 9.604585e-02 | 1.018 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 2.227395e-01 | 0.652 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 2.592206e-01 | 0.586 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 4.716515e-01 | 0.326 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 6.250821e-01 | 0.204 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 9.079514e-02 | 1.042 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 4.421164e-01 | 0.354 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 5.129064e-01 | 0.290 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 6.189672e-01 | 0.208 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 4.471659e-01 | 0.350 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 4.269220e-01 | 0.370 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.389587e-01 | 0.622 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 2.520281e-01 | 0.599 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 5.489909e-01 | 0.260 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 3.749594e-01 | 0.426 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 1.541585e-01 | 0.812 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 3.312186e-01 | 0.480 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 5.390715e-01 | 0.268 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 1.603475e-01 | 0.795 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 4.624622e-01 | 0.335 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 3.534176e-01 | 0.452 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.615569e-01 | 0.792 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 1.507430e-01 | 0.822 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 2.861667e-01 | 0.543 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 5.344357e-01 | 0.272 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.456784e-01 | 0.837 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 5.344357e-01 | 0.272 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 2.000291e-01 | 0.699 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.049007e-01 | 0.688 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 2.910307e-01 | 0.536 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 1.339473e-01 | 0.873 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 1.605919e-01 | 0.794 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 2.178688e-01 | 0.662 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.762645e-01 | 0.754 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 4.363231e-01 | 0.360 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 4.363231e-01 | 0.360 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 4.363231e-01 | 0.360 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 1.493828e-01 | 0.826 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.008475e-01 | 0.697 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.719376e-01 | 0.566 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 3.405060e-01 | 0.468 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.547117e-01 | 0.810 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 4.389830e-01 | 0.358 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 3.735678e-01 | 0.428 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 4.767412e-01 | 0.322 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 5.518528e-01 | 0.258 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 4.251266e-01 | 0.371 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 3.917750e-01 | 0.407 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 3.660426e-01 | 0.436 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 4.118959e-01 | 0.385 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 5.129064e-01 | 0.290 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 5.129064e-01 | 0.290 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 5.129064e-01 | 0.290 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 4.319472e-01 | 0.365 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 4.151142e-01 | 0.382 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 5.473806e-01 | 0.262 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 6.004131e-01 | 0.222 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 6.004131e-01 | 0.222 | 0 | 0 |
| Formation of the Editosome | R-HSA-75094 | 6.004131e-01 | 0.222 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 6.004131e-01 | 0.222 | 0 | 0 |
| Ceramide signalling | R-HSA-193681 | 6.004131e-01 | 0.222 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 6.004131e-01 | 0.222 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 6.004131e-01 | 0.222 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 5.232003e-01 | 0.281 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 5.105384e-01 | 0.292 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 4.555247e-01 | 0.341 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 5.464746e-01 | 0.262 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 5.801057e-01 | 0.236 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 5.801057e-01 | 0.236 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 5.294424e-01 | 0.276 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 5.297450e-01 | 0.276 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 5.297450e-01 | 0.276 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 5.691429e-01 | 0.245 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 5.916595e-01 | 0.228 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 6.110560e-01 | 0.214 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 6.250821e-01 | 0.204 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 4.840302e-01 | 0.315 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 7.308230e-02 | 1.136 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 4.053672e-01 | 0.392 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 4.723760e-01 | 0.326 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 4.657044e-01 | 0.332 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 4.908454e-01 | 0.309 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 6.156353e-01 | 0.211 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 6.250821e-01 | 0.204 | 0 | 0 |
| S Phase | R-HSA-69242 | 6.251088e-01 | 0.204 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 1.260496e-01 | 0.899 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 1.237067e-01 | 0.908 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 2.719805e-01 | 0.565 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 4.423722e-01 | 0.354 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 4.058844e-01 | 0.392 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 6.402319e-01 | 0.194 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 1.649968e-01 | 0.783 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 1.335235e-01 | 0.874 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 3.152262e-01 | 0.501 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 4.002199e-01 | 0.398 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 4.750338e-01 | 0.323 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 2.903604e-01 | 0.537 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 3.849010e-01 | 0.415 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 3.004338e-01 | 0.522 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 1.605919e-01 | 0.794 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 8.395606e-02 | 1.076 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 9.726599e-02 | 1.012 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 3.997786e-01 | 0.398 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 4.389830e-01 | 0.358 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 3.741041e-01 | 0.427 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 4.048904e-01 | 0.393 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 4.337047e-01 | 0.363 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 5.295795e-01 | 0.276 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 5.458848e-01 | 0.263 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 6.352669e-01 | 0.197 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 1.834215e-01 | 0.737 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 1.493828e-01 | 0.826 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 2.878969e-01 | 0.541 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 6.125093e-01 | 0.213 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 4.389380e-01 | 0.358 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.179255e-01 | 0.498 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 3.997786e-01 | 0.398 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 4.973948e-01 | 0.303 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 3.227372e-01 | 0.491 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.629189e-01 | 0.788 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 5.518528e-01 | 0.258 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 4.251266e-01 | 0.371 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 5.473806e-01 | 0.262 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 6.004131e-01 | 0.222 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 5.472522e-01 | 0.262 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 6.110560e-01 | 0.214 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 3.005539e-01 | 0.522 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 3.005539e-01 | 0.522 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 3.155730e-01 | 0.501 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 5.055781e-01 | 0.296 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 5.483074e-01 | 0.261 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 3.142521e-01 | 0.503 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 3.094689e-01 | 0.509 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 3.997786e-01 | 0.398 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 5.147179e-01 | 0.288 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 5.722972e-01 | 0.242 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 4.908454e-01 | 0.309 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 5.925386e-01 | 0.227 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 5.346767e-01 | 0.272 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 4.259233e-01 | 0.371 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 3.261493e-01 | 0.487 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.187429e-01 | 0.925 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 4.619125e-01 | 0.335 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 1.445935e-01 | 0.840 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 3.596356e-01 | 0.444 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 2.910307e-01 | 0.536 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 2.910307e-01 | 0.536 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 2.337714e-01 | 0.631 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 3.678351e-01 | 0.434 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 1.762645e-01 | 0.754 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 8.395606e-02 | 1.076 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 4.363231e-01 | 0.360 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 3.593337e-01 | 0.445 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 3.405060e-01 | 0.468 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 4.973948e-01 | 0.303 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 4.973948e-01 | 0.303 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.861325e-01 | 0.730 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 4.322869e-01 | 0.364 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 4.767412e-01 | 0.322 | 0 | 0 |
| Biosynthesis of DPAn-3-derived 13-series resolvins | R-HSA-9026403 | 5.518528e-01 | 0.258 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 5.518528e-01 | 0.258 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 4.624622e-01 | 0.335 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 6.004131e-01 | 0.222 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 6.004131e-01 | 0.222 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 5.462687e-01 | 0.263 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 5.726197e-01 | 0.242 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 5.691429e-01 | 0.245 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 6.437141e-01 | 0.191 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 6.437141e-01 | 0.191 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 5.831805e-01 | 0.234 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 3.959728e-01 | 0.402 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 1.446758e-01 | 0.840 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 4.502621e-01 | 0.347 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 4.036702e-01 | 0.394 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 4.802795e-01 | 0.319 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 2.629442e-01 | 0.580 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 1.652329e-01 | 0.782 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 2.558981e-01 | 0.592 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.605919e-01 | 0.794 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 4.851831e-01 | 0.314 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 4.404843e-01 | 0.356 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 1.813437e-01 | 0.741 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 2.759164e-01 | 0.559 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 4.363231e-01 | 0.360 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 2.217075e-01 | 0.654 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 5.321981e-01 | 0.274 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 5.726197e-01 | 0.242 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 4.243006e-01 | 0.372 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.243006e-01 | 0.372 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 5.660257e-01 | 0.247 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 1.920767e-01 | 0.717 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 9.604585e-02 | 1.018 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 3.179255e-01 | 0.498 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 3.179255e-01 | 0.498 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 4.363231e-01 | 0.360 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 4.363231e-01 | 0.360 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 3.593337e-01 | 0.445 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 3.593337e-01 | 0.445 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 4.973948e-01 | 0.303 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.973948e-01 | 0.303 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 5.518528e-01 | 0.258 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 5.518528e-01 | 0.258 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 2.522366e-01 | 0.598 | 0 | 0 |
| Estrogen biosynthesis | R-HSA-193144 | 5.473806e-01 | 0.262 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 6.004131e-01 | 0.222 | 0 | 0 |
| Acetylcholine inhibits contraction of outer hair cells | R-HSA-9667769 | 6.004131e-01 | 0.222 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 5.464746e-01 | 0.262 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 6.437141e-01 | 0.191 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 6.437141e-01 | 0.191 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 7.187363e-02 | 1.143 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 2.519323e-01 | 0.599 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 5.473806e-01 | 0.262 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 5.472522e-01 | 0.262 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.762645e-01 | 0.754 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 2.785292e-01 | 0.555 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 6.004131e-01 | 0.222 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 6.004131e-01 | 0.222 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 6.004131e-01 | 0.222 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 6.004131e-01 | 0.222 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 6.004131e-01 | 0.222 | 0 | 0 |
| Lipid particle organization | R-HSA-8964572 | 6.437141e-01 | 0.191 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 6.437141e-01 | 0.191 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 5.662512e-01 | 0.247 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 1.493828e-01 | 0.826 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 4.974111e-01 | 0.303 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 4.196904e-01 | 0.377 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 4.974111e-01 | 0.303 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.719376e-01 | 0.566 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 6.195411e-01 | 0.208 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 1.886660e-01 | 0.724 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 6.004131e-01 | 0.222 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.518528e-01 | 0.258 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 6.402319e-01 | 0.194 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 3.298359e-01 | 0.482 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 4.076267e-01 | 0.390 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 4.896488e-01 | 0.310 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.389830e-01 | 0.358 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 4.951611e-01 | 0.305 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 4.908454e-01 | 0.309 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 6.223643e-01 | 0.206 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 6.457023e-01 | 0.190 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 6.457023e-01 | 0.190 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 6.489965e-01 | 0.188 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 6.516334e-01 | 0.186 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 6.526520e-01 | 0.185 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 6.530648e-01 | 0.185 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 6.530648e-01 | 0.185 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 6.530648e-01 | 0.185 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 6.530648e-01 | 0.185 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 6.555732e-01 | 0.183 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 6.584596e-01 | 0.181 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 6.606988e-01 | 0.180 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 6.608236e-01 | 0.180 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 6.608236e-01 | 0.180 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 6.608236e-01 | 0.180 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 6.637301e-01 | 0.178 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 6.676544e-01 | 0.175 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 6.676544e-01 | 0.175 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 6.676544e-01 | 0.175 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 6.676544e-01 | 0.175 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 6.676544e-01 | 0.175 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 6.676544e-01 | 0.175 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 6.676544e-01 | 0.175 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 6.679984e-01 | 0.175 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 6.679984e-01 | 0.175 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 6.697890e-01 | 0.174 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 6.697890e-01 | 0.174 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 6.722433e-01 | 0.172 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 6.722433e-01 | 0.172 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 6.722433e-01 | 0.172 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 6.722433e-01 | 0.172 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 6.722433e-01 | 0.172 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 6.722433e-01 | 0.172 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 6.760166e-01 | 0.170 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 6.823250e-01 | 0.166 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 6.823250e-01 | 0.166 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 6.823250e-01 | 0.166 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 6.823250e-01 | 0.166 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 6.823250e-01 | 0.166 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis | R-HSA-9632974 | 6.823250e-01 | 0.166 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 6.823250e-01 | 0.166 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 6.823250e-01 | 0.166 | 0 | 0 |
| mRNA Editing: C to U Conversion | R-HSA-72200 | 6.823250e-01 | 0.166 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 6.823250e-01 | 0.166 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 6.823250e-01 | 0.166 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 6.823250e-01 | 0.166 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 6.823250e-01 | 0.166 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 6.823250e-01 | 0.166 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 6.823250e-01 | 0.166 | 0 | 0 |
| Glycoprotein hormones | R-HSA-209822 | 6.823250e-01 | 0.166 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 6.823250e-01 | 0.166 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 6.839322e-01 | 0.165 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 6.906760e-01 | 0.161 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 6.906760e-01 | 0.161 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 6.906760e-01 | 0.161 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 6.906760e-01 | 0.161 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 6.921738e-01 | 0.160 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 6.927336e-01 | 0.159 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 6.933608e-01 | 0.159 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 6.933608e-01 | 0.159 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 6.933608e-01 | 0.159 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 6.933608e-01 | 0.159 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 6.933608e-01 | 0.159 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 6.933608e-01 | 0.159 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 6.933608e-01 | 0.159 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 6.934563e-01 | 0.159 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 6.942822e-01 | 0.158 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 6.959216e-01 | 0.157 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 6.960575e-01 | 0.157 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 6.963507e-01 | 0.157 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 6.994483e-01 | 0.155 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 7.033001e-01 | 0.153 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 7.038905e-01 | 0.152 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 7.083596e-01 | 0.150 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 7.083596e-01 | 0.150 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 7.083596e-01 | 0.150 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 7.083596e-01 | 0.150 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 7.083866e-01 | 0.150 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 7.094625e-01 | 0.149 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 7.094625e-01 | 0.149 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 7.167536e-01 | 0.145 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.167536e-01 | 0.145 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 7.167536e-01 | 0.145 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 7.167536e-01 | 0.145 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 7.167536e-01 | 0.145 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 7.167536e-01 | 0.145 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 7.167536e-01 | 0.145 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 7.167536e-01 | 0.145 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 7.167536e-01 | 0.145 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 7.167536e-01 | 0.145 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 7.167536e-01 | 0.145 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 7.167536e-01 | 0.145 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 7.172169e-01 | 0.144 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 7.172169e-01 | 0.144 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 7.174011e-01 | 0.144 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 7.174011e-01 | 0.144 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 7.252946e-01 | 0.139 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 7.254029e-01 | 0.139 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 7.254029e-01 | 0.139 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 7.254029e-01 | 0.139 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 7.254029e-01 | 0.139 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 7.254029e-01 | 0.139 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 7.286478e-01 | 0.137 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 7.286478e-01 | 0.137 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 7.286478e-01 | 0.137 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 7.286478e-01 | 0.137 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 7.301317e-01 | 0.137 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 7.348502e-01 | 0.134 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 7.350738e-01 | 0.134 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 7.386961e-01 | 0.132 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 7.398343e-01 | 0.131 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 7.398343e-01 | 0.131 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 7.398343e-01 | 0.131 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 7.398343e-01 | 0.131 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 7.398343e-01 | 0.131 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 7.398343e-01 | 0.131 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 7.398343e-01 | 0.131 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 7.398343e-01 | 0.131 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 7.400822e-01 | 0.131 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 7.400822e-01 | 0.131 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 7.407598e-01 | 0.130 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 7.414859e-01 | 0.130 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 7.468233e-01 | 0.127 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 7.474528e-01 | 0.126 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 7.474528e-01 | 0.126 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 7.474528e-01 | 0.126 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 7.474528e-01 | 0.126 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 7.474528e-01 | 0.126 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 7.474528e-01 | 0.126 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 7.474528e-01 | 0.126 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 7.474528e-01 | 0.126 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 7.474528e-01 | 0.126 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 7.474528e-01 | 0.126 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 7.474528e-01 | 0.126 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 7.474528e-01 | 0.126 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 7.474528e-01 | 0.126 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 7.474528e-01 | 0.126 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 7.474528e-01 | 0.126 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 7.490960e-01 | 0.125 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 7.533859e-01 | 0.123 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 7.537565e-01 | 0.123 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 7.541771e-01 | 0.123 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 7.559065e-01 | 0.122 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 7.607263e-01 | 0.119 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 7.607263e-01 | 0.119 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 7.607263e-01 | 0.119 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 7.607263e-01 | 0.119 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 7.607263e-01 | 0.119 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 7.614402e-01 | 0.118 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 7.616754e-01 | 0.118 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 7.627823e-01 | 0.118 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 7.640116e-01 | 0.117 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 7.640116e-01 | 0.117 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 7.640116e-01 | 0.117 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 7.640116e-01 | 0.117 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 7.646593e-01 | 0.117 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 7.676925e-01 | 0.115 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 7.710337e-01 | 0.113 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 7.716720e-01 | 0.113 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 7.748263e-01 | 0.111 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 7.748263e-01 | 0.111 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 7.748263e-01 | 0.111 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 7.748263e-01 | 0.111 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 7.748263e-01 | 0.111 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 7.748263e-01 | 0.111 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 7.748263e-01 | 0.111 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 7.748263e-01 | 0.111 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 7.748263e-01 | 0.111 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 7.748263e-01 | 0.111 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 7.748263e-01 | 0.111 | 0 | 0 |
| Peptide hormone biosynthesis | R-HSA-209952 | 7.748263e-01 | 0.111 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 7.748263e-01 | 0.111 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 7.776448e-01 | 0.109 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 7.783076e-01 | 0.109 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 7.783076e-01 | 0.109 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 7.783076e-01 | 0.109 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 7.801477e-01 | 0.108 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 7.801477e-01 | 0.108 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 7.801477e-01 | 0.108 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 7.802387e-01 | 0.108 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 7.809758e-01 | 0.107 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 7.856914e-01 | 0.105 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 7.856914e-01 | 0.105 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 7.856914e-01 | 0.105 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 7.883489e-01 | 0.103 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 7.883489e-01 | 0.103 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 7.918082e-01 | 0.101 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 7.955340e-01 | 0.099 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 7.955340e-01 | 0.099 | 0 | 0 |
| Synthesis of glycosylphosphatidylinositol (GPI) | R-HSA-162710 | 7.955340e-01 | 0.099 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 7.981717e-01 | 0.098 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 7.981717e-01 | 0.098 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 7.981717e-01 | 0.098 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 7.981717e-01 | 0.098 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 7.981717e-01 | 0.098 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 7.981717e-01 | 0.098 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 7.981717e-01 | 0.098 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 7.989733e-01 | 0.097 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 7.990154e-01 | 0.097 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 7.990154e-01 | 0.097 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 7.992342e-01 | 0.097 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 7.992342e-01 | 0.097 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 7.992342e-01 | 0.097 | 0 | 0 |
| FGFR2b ligand binding and activation | R-HSA-190377 | 7.992342e-01 | 0.097 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 7.992342e-01 | 0.097 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 7.992342e-01 | 0.097 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 7.992342e-01 | 0.097 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 7.992342e-01 | 0.097 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 7.992342e-01 | 0.097 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 7.992342e-01 | 0.097 | 0 | 0 |
| Biosynthesis of DPAn-3-derived maresins | R-HSA-9026290 | 7.992342e-01 | 0.097 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 7.992342e-01 | 0.097 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 8.048393e-01 | 0.094 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 8.099293e-01 | 0.092 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 8.099293e-01 | 0.092 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 8.116039e-01 | 0.091 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 8.116613e-01 | 0.091 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 8.132144e-01 | 0.090 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 8.148730e-01 | 0.089 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 8.148730e-01 | 0.089 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 8.148730e-01 | 0.089 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 8.148730e-01 | 0.089 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 8.148730e-01 | 0.089 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 8.169641e-01 | 0.088 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 8.186942e-01 | 0.087 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 8.193034e-01 | 0.087 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 8.209977e-01 | 0.086 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 8.209977e-01 | 0.086 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 8.209977e-01 | 0.086 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 8.209977e-01 | 0.086 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 8.209977e-01 | 0.086 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 8.209977e-01 | 0.086 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 8.209977e-01 | 0.086 | 0 | 0 |
| Uptake of dietary cobalamins into enterocytes | R-HSA-9758881 | 8.209977e-01 | 0.086 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 8.226178e-01 | 0.085 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 8.234581e-01 | 0.084 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 8.234581e-01 | 0.084 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 8.236485e-01 | 0.084 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 8.236485e-01 | 0.084 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 8.236485e-01 | 0.084 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 8.243781e-01 | 0.084 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 8.268753e-01 | 0.083 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 8.297807e-01 | 0.081 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 8.303265e-01 | 0.081 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 8.303265e-01 | 0.081 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 8.303265e-01 | 0.081 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 8.303265e-01 | 0.081 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 8.303265e-01 | 0.081 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 8.303265e-01 | 0.081 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 8.303265e-01 | 0.081 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 8.315338e-01 | 0.080 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 8.328100e-01 | 0.079 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 8.343263e-01 | 0.079 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 8.349972e-01 | 0.078 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 8.361555e-01 | 0.078 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 8.361555e-01 | 0.078 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 8.371125e-01 | 0.077 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 8.371125e-01 | 0.077 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 8.404031e-01 | 0.076 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 8.404031e-01 | 0.076 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 8.404031e-01 | 0.076 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 8.404031e-01 | 0.076 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 8.404031e-01 | 0.076 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.404031e-01 | 0.076 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 8.404031e-01 | 0.076 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 8.404031e-01 | 0.076 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 8.404031e-01 | 0.076 | 0 | 0 |
| Biosynthesis of DPAn-3-derived protectins and resolvins | R-HSA-9026286 | 8.404031e-01 | 0.076 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.404031e-01 | 0.076 | 0 | 0 |
| Diseases associated with surfactant metabolism | R-HSA-5687613 | 8.404031e-01 | 0.076 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 8.404031e-01 | 0.076 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 8.421279e-01 | 0.075 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 8.446065e-01 | 0.073 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 8.446065e-01 | 0.073 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 8.446065e-01 | 0.073 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 8.446065e-01 | 0.073 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 8.450747e-01 | 0.073 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 8.454044e-01 | 0.073 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 8.480570e-01 | 0.072 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 8.480570e-01 | 0.072 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 8.536841e-01 | 0.069 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 8.558650e-01 | 0.068 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 8.560968e-01 | 0.067 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 8.560968e-01 | 0.067 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 8.577058e-01 | 0.067 | 0 | 0 |
| FGFR2c ligand binding and activation | R-HSA-190375 | 8.577058e-01 | 0.067 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 8.577058e-01 | 0.067 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 8.577058e-01 | 0.067 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 8.577058e-01 | 0.067 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 8.577058e-01 | 0.067 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 8.577058e-01 | 0.067 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 8.577058e-01 | 0.067 | 0 | 0 |
| Mtb iron assimilation by chelation | R-HSA-1222449 | 8.577058e-01 | 0.067 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 8.577058e-01 | 0.067 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 8.577058e-01 | 0.067 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 8.577058e-01 | 0.067 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 8.577058e-01 | 0.067 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 8.577058e-01 | 0.067 | 0 | 0 |
| rRNA modification in the mitochondrion | R-HSA-6793080 | 8.577058e-01 | 0.067 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 8.577058e-01 | 0.067 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 8.577058e-01 | 0.067 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 8.577058e-01 | 0.067 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 8.577856e-01 | 0.067 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 8.577856e-01 | 0.067 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 8.577856e-01 | 0.067 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 8.593636e-01 | 0.066 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 8.625002e-01 | 0.064 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 8.642919e-01 | 0.063 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 8.654287e-01 | 0.063 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 8.654287e-01 | 0.063 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 8.696175e-01 | 0.061 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 8.696175e-01 | 0.061 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 8.696175e-01 | 0.061 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 8.699346e-01 | 0.061 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 8.699346e-01 | 0.061 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 8.699346e-01 | 0.061 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 8.731336e-01 | 0.059 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 8.731336e-01 | 0.059 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 8.731336e-01 | 0.059 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 8.731336e-01 | 0.059 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 8.731336e-01 | 0.059 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 8.731336e-01 | 0.059 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 8.731336e-01 | 0.059 | 0 | 0 |
| Biosynthesis of E-series 18(R)-resolvins | R-HSA-9023661 | 8.731336e-01 | 0.059 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 8.731336e-01 | 0.059 | 0 | 0 |
| Vitamin B2 (riboflavin) metabolism | R-HSA-196843 | 8.731336e-01 | 0.059 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.731336e-01 | 0.059 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 8.731336e-01 | 0.059 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 8.731336e-01 | 0.059 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 8.731336e-01 | 0.059 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 8.731336e-01 | 0.059 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 8.731336e-01 | 0.059 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 8.731336e-01 | 0.059 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 8.731973e-01 | 0.059 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 8.744425e-01 | 0.058 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 8.759949e-01 | 0.057 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.793490e-01 | 0.056 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 8.793490e-01 | 0.056 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 8.801612e-01 | 0.055 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 8.811221e-01 | 0.055 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 8.811221e-01 | 0.055 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 8.811221e-01 | 0.055 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 8.811221e-01 | 0.055 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 8.811221e-01 | 0.055 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 8.828058e-01 | 0.054 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 8.829295e-01 | 0.054 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 8.848107e-01 | 0.053 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 8.868894e-01 | 0.052 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 8.868894e-01 | 0.052 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 8.868894e-01 | 0.052 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 8.868894e-01 | 0.052 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 8.868894e-01 | 0.052 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 8.868894e-01 | 0.052 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 8.868894e-01 | 0.052 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 8.868894e-01 | 0.052 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 8.868894e-01 | 0.052 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 8.868894e-01 | 0.052 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 8.868894e-01 | 0.052 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 8.868894e-01 | 0.052 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 8.868894e-01 | 0.052 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 8.868894e-01 | 0.052 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 8.868894e-01 | 0.052 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 8.868894e-01 | 0.052 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 8.868894e-01 | 0.052 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 8.882773e-01 | 0.051 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 8.882773e-01 | 0.051 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 8.882773e-01 | 0.051 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 8.884288e-01 | 0.051 | 0 | 0 |
| Depurination | R-HSA-73927 | 8.884288e-01 | 0.051 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 8.884288e-01 | 0.051 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 8.885421e-01 | 0.051 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 8.885421e-01 | 0.051 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 8.885421e-01 | 0.051 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 8.885421e-01 | 0.051 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 8.885421e-01 | 0.051 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 8.885421e-01 | 0.051 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 8.909126e-01 | 0.050 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 8.914135e-01 | 0.050 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 8.914135e-01 | 0.050 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 8.914135e-01 | 0.050 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 8.914135e-01 | 0.050 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 8.934848e-01 | 0.049 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 8.955969e-01 | 0.048 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 8.955969e-01 | 0.048 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.968922e-01 | 0.047 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 8.968922e-01 | 0.047 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 8.969370e-01 | 0.047 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 8.984146e-01 | 0.047 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 8.984146e-01 | 0.047 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 8.991545e-01 | 0.046 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 8.991545e-01 | 0.046 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 8.991545e-01 | 0.046 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 8.991545e-01 | 0.046 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 8.991545e-01 | 0.046 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 8.991545e-01 | 0.046 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 8.991545e-01 | 0.046 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 8.991545e-01 | 0.046 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 8.991545e-01 | 0.046 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 8.991545e-01 | 0.046 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 8.991545e-01 | 0.046 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 8.991545e-01 | 0.046 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 9.008716e-01 | 0.045 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 9.008716e-01 | 0.045 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.008716e-01 | 0.045 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 9.012758e-01 | 0.045 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 9.022620e-01 | 0.045 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 9.030222e-01 | 0.044 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 9.047732e-01 | 0.043 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 9.047732e-01 | 0.043 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 9.050489e-01 | 0.043 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 9.061811e-01 | 0.043 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 9.071085e-01 | 0.042 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 9.095562e-01 | 0.041 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 9.095562e-01 | 0.041 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 9.100902e-01 | 0.041 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 9.100902e-01 | 0.041 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 9.100902e-01 | 0.041 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 9.100902e-01 | 0.041 | 0 | 0 |
| Vitamin B6 activation to pyridoxal phosphate | R-HSA-964975 | 9.100902e-01 | 0.041 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 9.100902e-01 | 0.041 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 9.100902e-01 | 0.041 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 9.100902e-01 | 0.041 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 9.120651e-01 | 0.040 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 9.120651e-01 | 0.040 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 9.120651e-01 | 0.040 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.121050e-01 | 0.040 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.121050e-01 | 0.040 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 9.121050e-01 | 0.040 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 9.121474e-01 | 0.040 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 9.129084e-01 | 0.040 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.138821e-01 | 0.039 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 9.144876e-01 | 0.039 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 9.175236e-01 | 0.037 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 9.175236e-01 | 0.037 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 9.175236e-01 | 0.037 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 9.175236e-01 | 0.037 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.177427e-01 | 0.037 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 9.182576e-01 | 0.037 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.182576e-01 | 0.037 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 9.189199e-01 | 0.037 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 9.189199e-01 | 0.037 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 9.189199e-01 | 0.037 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 9.189199e-01 | 0.037 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.189199e-01 | 0.037 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 9.198407e-01 | 0.036 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 9.198407e-01 | 0.036 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 9.198407e-01 | 0.036 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 9.198407e-01 | 0.036 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 9.198407e-01 | 0.036 | 0 | 0 |
| Biosynthesis of aspirin-triggered D-series resolvins | R-HSA-9020265 | 9.198407e-01 | 0.036 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 9.198407e-01 | 0.036 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 9.198407e-01 | 0.036 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 9.198407e-01 | 0.036 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 9.198407e-01 | 0.036 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.200801e-01 | 0.036 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 9.212423e-01 | 0.036 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 9.240566e-01 | 0.034 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 9.245526e-01 | 0.034 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.248273e-01 | 0.034 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.248273e-01 | 0.034 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 9.269109e-01 | 0.033 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.279060e-01 | 0.032 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 9.285342e-01 | 0.032 | 0 | 0 |
| Activated point mutants of FGFR2 | R-HSA-2033519 | 9.285342e-01 | 0.032 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 9.285342e-01 | 0.032 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 9.285342e-01 | 0.032 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 9.285342e-01 | 0.032 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 9.285342e-01 | 0.032 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 9.285342e-01 | 0.032 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.285342e-01 | 0.032 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.306709e-01 | 0.031 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 9.306709e-01 | 0.031 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 9.310224e-01 | 0.031 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.311077e-01 | 0.031 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.311217e-01 | 0.031 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 9.311217e-01 | 0.031 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 9.315175e-01 | 0.031 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 9.315175e-01 | 0.031 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.324170e-01 | 0.030 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 9.345565e-01 | 0.029 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 9.345565e-01 | 0.029 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 9.346207e-01 | 0.029 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 9.362854e-01 | 0.029 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 9.362854e-01 | 0.029 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.362854e-01 | 0.029 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.362854e-01 | 0.029 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 9.362854e-01 | 0.029 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.365669e-01 | 0.028 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.365669e-01 | 0.028 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 9.376413e-01 | 0.028 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.392967e-01 | 0.027 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.416119e-01 | 0.026 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.416119e-01 | 0.026 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 9.431962e-01 | 0.025 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 9.431962e-01 | 0.025 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 9.431962e-01 | 0.025 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 9.431962e-01 | 0.025 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.431962e-01 | 0.025 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.431962e-01 | 0.025 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.431962e-01 | 0.025 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 9.431962e-01 | 0.025 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 9.431962e-01 | 0.025 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 9.432428e-01 | 0.025 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.432428e-01 | 0.025 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 9.434540e-01 | 0.025 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.437223e-01 | 0.025 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 9.455072e-01 | 0.024 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 9.462826e-01 | 0.024 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.462826e-01 | 0.024 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.483633e-01 | 0.023 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 9.483633e-01 | 0.023 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.483633e-01 | 0.023 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.487597e-01 | 0.023 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 9.493400e-01 | 0.023 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 9.493579e-01 | 0.023 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 9.493579e-01 | 0.023 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 9.493579e-01 | 0.023 | 0 | 0 |
| FGFR2 ligand binding and activation | R-HSA-190241 | 9.493579e-01 | 0.023 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 9.493579e-01 | 0.023 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 9.493579e-01 | 0.023 | 0 | 0 |
| Biosynthesis of E-series 18(S)-resolvins | R-HSA-9018896 | 9.493579e-01 | 0.023 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 9.493579e-01 | 0.023 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 9.493579e-01 | 0.023 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.493579e-01 | 0.023 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 9.493579e-01 | 0.023 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 9.493579e-01 | 0.023 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.495539e-01 | 0.022 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 9.506037e-01 | 0.022 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 9.507757e-01 | 0.022 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 9.509311e-01 | 0.022 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 9.509311e-01 | 0.022 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.530411e-01 | 0.021 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.530411e-01 | 0.021 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 9.543223e-01 | 0.020 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 9.545987e-01 | 0.020 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 9.548515e-01 | 0.020 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.548515e-01 | 0.020 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 9.548515e-01 | 0.020 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 9.548515e-01 | 0.020 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 9.563003e-01 | 0.019 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.573121e-01 | 0.019 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 9.583773e-01 | 0.018 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 9.586262e-01 | 0.018 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.596412e-01 | 0.018 | 0 | 0 |
| Biosynthesis of D-series resolvins | R-HSA-9018676 | 9.597494e-01 | 0.018 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.597494e-01 | 0.018 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.597494e-01 | 0.018 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.597494e-01 | 0.018 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 9.597494e-01 | 0.018 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 9.604626e-01 | 0.018 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.604713e-01 | 0.018 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 9.604713e-01 | 0.018 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 9.604713e-01 | 0.018 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 9.609883e-01 | 0.017 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 9.612094e-01 | 0.017 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.612094e-01 | 0.017 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.612094e-01 | 0.017 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 9.626402e-01 | 0.017 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 9.641163e-01 | 0.016 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 9.641163e-01 | 0.016 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 9.641163e-01 | 0.016 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.641163e-01 | 0.016 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.641163e-01 | 0.016 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.641163e-01 | 0.016 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.643709e-01 | 0.016 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.646720e-01 | 0.016 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.647639e-01 | 0.016 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 9.647719e-01 | 0.016 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.648426e-01 | 0.016 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 9.654658e-01 | 0.015 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 9.677429e-01 | 0.014 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.680039e-01 | 0.014 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 9.680096e-01 | 0.014 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.680096e-01 | 0.014 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 9.680096e-01 | 0.014 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 9.680096e-01 | 0.014 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.680096e-01 | 0.014 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 9.680096e-01 | 0.014 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 9.680096e-01 | 0.014 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 9.680096e-01 | 0.014 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.680484e-01 | 0.014 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 9.682816e-01 | 0.014 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.699595e-01 | 0.013 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 9.699595e-01 | 0.013 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 9.704161e-01 | 0.013 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 9.705423e-01 | 0.013 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 9.705503e-01 | 0.013 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 9.709559e-01 | 0.013 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 9.709559e-01 | 0.013 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 9.709559e-01 | 0.013 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 9.709559e-01 | 0.013 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 9.711839e-01 | 0.013 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 9.714807e-01 | 0.013 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 9.714807e-01 | 0.013 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 9.714807e-01 | 0.013 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 9.714807e-01 | 0.013 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 9.714807e-01 | 0.013 | 0 | 0 |
| Alpha-oxidation of phytanate | R-HSA-389599 | 9.714807e-01 | 0.013 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.714807e-01 | 0.013 | 0 | 0 |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | R-HSA-9027604 | 9.714807e-01 | 0.013 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.714807e-01 | 0.013 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 9.726678e-01 | 0.012 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 9.730961e-01 | 0.012 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 9.742670e-01 | 0.011 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 9.745753e-01 | 0.011 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 9.745753e-01 | 0.011 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.745753e-01 | 0.011 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 9.754351e-01 | 0.011 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.756996e-01 | 0.011 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.760914e-01 | 0.011 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.760914e-01 | 0.011 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.761924e-01 | 0.010 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 9.771590e-01 | 0.010 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 9.772320e-01 | 0.010 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.772320e-01 | 0.010 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.772352e-01 | 0.010 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 9.773343e-01 | 0.010 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.773343e-01 | 0.010 | 0 | 0 |
| Biosynthesis of DPAn-3 SPMs | R-HSA-9025094 | 9.773343e-01 | 0.010 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.773343e-01 | 0.010 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.773343e-01 | 0.010 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.773343e-01 | 0.010 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 9.773343e-01 | 0.010 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.773343e-01 | 0.010 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.773343e-01 | 0.010 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.781059e-01 | 0.010 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.782013e-01 | 0.010 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.783179e-01 | 0.010 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.783179e-01 | 0.010 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.789430e-01 | 0.009 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 9.794123e-01 | 0.009 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.796842e-01 | 0.009 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 9.797591e-01 | 0.009 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 9.798000e-01 | 0.009 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 9.800384e-01 | 0.009 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.803430e-01 | 0.009 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 9.803430e-01 | 0.009 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 9.815066e-01 | 0.008 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.819870e-01 | 0.008 | 0 | 0 |
| Biosynthesis of EPA-derived SPMs | R-HSA-9018679 | 9.819870e-01 | 0.008 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 9.819870e-01 | 0.008 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.819870e-01 | 0.008 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.819870e-01 | 0.008 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 9.821840e-01 | 0.008 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 9.821840e-01 | 0.008 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 9.821840e-01 | 0.008 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.825358e-01 | 0.008 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 9.838571e-01 | 0.007 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 9.839421e-01 | 0.007 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.839421e-01 | 0.007 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.840245e-01 | 0.007 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.840245e-01 | 0.007 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 9.848979e-01 | 0.007 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 9.853770e-01 | 0.006 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.853770e-01 | 0.006 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 9.853912e-01 | 0.006 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 9.856850e-01 | 0.006 | 0 | 0 |
| Biosynthesis of DPA-derived SPMs | R-HSA-9018683 | 9.856850e-01 | 0.006 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 9.858215e-01 | 0.006 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.858809e-01 | 0.006 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 9.862199e-01 | 0.006 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 9.866453e-01 | 0.006 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.866453e-01 | 0.006 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 9.867573e-01 | 0.006 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 9.869945e-01 | 0.006 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 9.872389e-01 | 0.006 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.877051e-01 | 0.005 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.879588e-01 | 0.005 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 9.880104e-01 | 0.005 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.880104e-01 | 0.005 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.886242e-01 | 0.005 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 9.890000e-01 | 0.005 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 9.891475e-01 | 0.005 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 9.891475e-01 | 0.005 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 9.891475e-01 | 0.005 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.891475e-01 | 0.005 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.898592e-01 | 0.004 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.898592e-01 | 0.004 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.907497e-01 | 0.004 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.909601e-01 | 0.004 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.909601e-01 | 0.004 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 9.909601e-01 | 0.004 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.909601e-01 | 0.004 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 9.909601e-01 | 0.004 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.909601e-01 | 0.004 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.909601e-01 | 0.004 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 9.909601e-01 | 0.004 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 9.909749e-01 | 0.004 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 9.911147e-01 | 0.004 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.915137e-01 | 0.004 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.915137e-01 | 0.004 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 9.915335e-01 | 0.004 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.919416e-01 | 0.004 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 9.919416e-01 | 0.004 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.919416e-01 | 0.004 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.919416e-01 | 0.004 | 0 | 0 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | R-HSA-193775 | 9.919416e-01 | 0.004 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 9.919502e-01 | 0.004 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 9.919630e-01 | 0.004 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.919630e-01 | 0.004 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.922562e-01 | 0.003 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 9.927319e-01 | 0.003 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 9.928166e-01 | 0.003 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 9.928166e-01 | 0.003 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 9.928166e-01 | 0.003 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.928166e-01 | 0.003 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 9.931165e-01 | 0.003 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.931374e-01 | 0.003 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.931374e-01 | 0.003 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.931374e-01 | 0.003 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 9.934287e-01 | 0.003 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.935966e-01 | 0.003 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 9.935966e-01 | 0.003 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.935966e-01 | 0.003 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.935966e-01 | 0.003 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 9.940599e-01 | 0.003 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 9.940599e-01 | 0.003 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 9.940599e-01 | 0.003 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.941258e-01 | 0.003 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.942810e-01 | 0.002 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.942920e-01 | 0.002 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 9.945132e-01 | 0.002 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 9.946315e-01 | 0.002 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.947549e-01 | 0.002 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.949119e-01 | 0.002 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 9.949119e-01 | 0.002 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.949119e-01 | 0.002 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.949119e-01 | 0.002 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.949119e-01 | 0.002 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.949432e-01 | 0.002 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.949432e-01 | 0.002 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.951019e-01 | 0.002 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 9.951491e-01 | 0.002 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 9.951909e-01 | 0.002 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 9.954645e-01 | 0.002 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.954645e-01 | 0.002 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.954645e-01 | 0.002 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 9.954753e-01 | 0.002 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 9.955544e-01 | 0.002 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 9.956176e-01 | 0.002 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.958520e-01 | 0.002 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.959507e-01 | 0.002 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 9.959571e-01 | 0.002 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.959571e-01 | 0.002 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.960416e-01 | 0.002 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 9.962208e-01 | 0.002 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 9.963126e-01 | 0.002 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.964252e-01 | 0.002 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.964252e-01 | 0.002 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.967722e-01 | 0.001 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.967722e-01 | 0.001 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.967877e-01 | 0.001 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.968539e-01 | 0.001 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.969443e-01 | 0.001 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.969443e-01 | 0.001 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.971367e-01 | 0.001 | 0 | 0 |
| Pyrimidine catabolism | R-HSA-73621 | 9.971367e-01 | 0.001 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.971367e-01 | 0.001 | 0 | 0 |
| Protein folding | R-HSA-391251 | 9.971584e-01 | 0.001 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.974477e-01 | 0.001 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.974477e-01 | 0.001 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.976202e-01 | 0.001 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.976617e-01 | 0.001 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.976728e-01 | 0.001 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.976988e-01 | 0.001 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.977250e-01 | 0.001 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.977250e-01 | 0.001 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.977250e-01 | 0.001 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.977250e-01 | 0.001 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 9.977624e-01 | 0.001 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.979610e-01 | 0.001 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.979722e-01 | 0.001 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.980677e-01 | 0.001 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 9.981925e-01 | 0.001 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.981925e-01 | 0.001 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.982570e-01 | 0.001 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.983889e-01 | 0.001 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 9.984280e-01 | 0.001 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.985640e-01 | 0.001 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.986099e-01 | 0.001 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.987218e-01 | 0.001 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.988110e-01 | 0.001 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.988477e-01 | 0.001 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.988477e-01 | 0.001 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.988477e-01 | 0.001 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.988592e-01 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.988592e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.989613e-01 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.990277e-01 | 0.000 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.990937e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.991564e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.991942e-01 | 0.000 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 9.992399e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.993583e-01 | 0.000 | 0 | 0 |
| Digestion | R-HSA-8935690 | 9.993583e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.994143e-01 | 0.000 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.994281e-01 | 0.000 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.994443e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.995361e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.995457e-01 | 0.000 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.995457e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.996391e-01 | 0.000 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.996782e-01 | 0.000 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.996784e-01 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 9.997133e-01 | 0.000 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.997270e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.997419e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.997445e-01 | 0.000 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.997656e-01 | 0.000 | 0 | 0 |
| Latent infection - Other responses of Mtb to phagocytosis | R-HSA-1222499 | 9.997723e-01 | 0.000 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.997749e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.997988e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.997998e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.998192e-01 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.998254e-01 | 0.000 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.998354e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.998388e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.998449e-01 | 0.000 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.998587e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.998587e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.998859e-01 | 0.000 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.998959e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999020e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.999094e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999173e-01 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.999252e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.999280e-01 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.999453e-01 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.999453e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.999491e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999546e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.999548e-01 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 9.999618e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999635e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999640e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999745e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999820e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999828e-01 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.999839e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.999899e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999928e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999951e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999952e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999958e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999965e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999970e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999976e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.999983e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999989e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.999993e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999998e-01 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 9.999999e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999999e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999999e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.000000e+00 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000e+00 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cellular responses to stimuli | R-HSA-8953897 | 5.995204e-14 | 13.222 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.415534e-13 | 12.849 | 0 | 0 |
| M Phase | R-HSA-68886 | 2.322587e-13 | 12.634 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 3.008704e-13 | 12.522 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.980194e-12 | 11.703 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.911582e-12 | 11.719 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.911582e-12 | 11.719 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.396327e-12 | 11.855 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 1.978084e-12 | 11.704 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.634892e-12 | 11.579 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 5.410339e-12 | 11.267 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 7.359446e-12 | 11.133 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 1.269262e-11 | 10.896 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.523115e-11 | 10.817 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 1.506462e-11 | 10.822 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 1.715605e-11 | 10.766 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.728628e-11 | 10.564 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 3.329825e-11 | 10.478 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 4.555711e-11 | 10.341 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 4.802636e-11 | 10.319 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 5.796852e-11 | 10.237 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.087054e-10 | 9.964 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 2.028557e-10 | 9.693 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 2.150781e-10 | 9.667 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 2.354590e-10 | 9.628 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 4.188040e-10 | 9.378 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 5.129958e-10 | 9.290 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 6.251965e-10 | 9.204 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 6.781132e-10 | 9.169 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.091234e-09 | 8.962 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.184963e-09 | 8.926 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.149216e-09 | 8.940 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 1.389406e-09 | 8.857 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 1.519603e-09 | 8.818 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.740661e-09 | 8.759 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 2.630257e-09 | 8.580 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 2.630257e-09 | 8.580 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.661378e-09 | 8.575 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.971577e-09 | 8.527 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 2.971577e-09 | 8.527 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 3.994882e-09 | 8.398 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 4.372406e-09 | 8.359 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 4.737448e-09 | 8.324 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 5.225962e-09 | 8.282 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 5.751376e-09 | 8.240 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 9.157618e-09 | 8.038 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 9.762616e-09 | 8.010 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 1.016078e-08 | 7.993 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 1.272454e-08 | 7.895 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 1.229834e-08 | 7.910 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 1.279113e-08 | 7.893 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 1.411940e-08 | 7.850 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 1.411940e-08 | 7.850 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.419326e-08 | 7.848 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.485850e-08 | 7.828 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 1.734263e-08 | 7.761 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.978400e-08 | 7.704 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 2.149381e-08 | 7.668 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 2.614469e-08 | 7.583 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 2.947700e-08 | 7.531 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 2.852625e-08 | 7.545 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 2.950177e-08 | 7.530 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 3.254587e-08 | 7.488 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 3.461568e-08 | 7.461 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 3.649538e-08 | 7.438 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 3.797366e-08 | 7.421 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 4.334008e-08 | 7.363 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 4.658679e-08 | 7.332 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 4.839179e-08 | 7.315 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 5.138525e-08 | 7.289 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 5.818854e-08 | 7.235 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 6.382380e-08 | 7.195 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 6.439569e-08 | 7.191 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 6.910472e-08 | 7.160 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 8.474154e-08 | 7.072 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 8.867009e-08 | 7.052 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 9.331204e-08 | 7.030 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 8.966187e-08 | 7.047 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.558011e-07 | 6.807 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 2.120353e-07 | 6.674 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 2.256431e-07 | 6.647 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 2.294921e-07 | 6.639 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 2.438830e-07 | 6.613 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 2.566436e-07 | 6.591 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 2.909295e-07 | 6.536 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 3.098624e-07 | 6.509 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 3.124366e-07 | 6.505 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 3.663550e-07 | 6.436 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 3.691811e-07 | 6.433 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 4.728743e-07 | 6.325 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 5.329643e-07 | 6.273 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 5.583445e-07 | 6.253 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 5.869140e-07 | 6.231 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 6.318008e-07 | 6.199 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 6.684369e-07 | 6.175 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 6.842211e-07 | 6.165 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 6.842211e-07 | 6.165 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 7.934177e-07 | 6.100 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 8.683515e-07 | 6.061 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 9.068280e-07 | 6.042 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 9.068280e-07 | 6.042 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 9.068280e-07 | 6.042 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 9.068280e-07 | 6.042 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 9.129394e-07 | 6.040 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 9.734495e-07 | 6.012 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 9.997735e-07 | 6.000 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 1.115362e-06 | 5.953 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 1.141188e-06 | 5.943 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 1.189884e-06 | 5.924 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.460088e-06 | 5.836 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 1.560937e-06 | 5.807 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 1.528646e-06 | 5.816 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.580733e-06 | 5.801 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 1.635066e-06 | 5.786 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 1.888602e-06 | 5.724 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.961269e-06 | 5.707 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 2.141373e-06 | 5.669 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 2.210179e-06 | 5.656 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 2.218192e-06 | 5.654 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 2.419505e-06 | 5.616 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 2.418365e-06 | 5.616 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 2.564024e-06 | 5.591 | 1 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 2.632434e-06 | 5.580 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 2.632434e-06 | 5.580 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 2.969613e-06 | 5.527 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 3.176772e-06 | 5.498 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 3.459793e-06 | 5.461 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 3.481322e-06 | 5.458 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 4.085584e-06 | 5.389 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 4.649772e-06 | 5.333 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 4.938886e-06 | 5.306 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 5.692042e-06 | 5.245 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 6.443984e-06 | 5.191 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 6.557376e-06 | 5.183 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 6.875521e-06 | 5.163 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 7.599133e-06 | 5.119 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 8.076865e-06 | 5.093 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 7.649305e-06 | 5.116 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 9.253128e-06 | 5.034 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 9.547677e-06 | 5.020 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 9.653195e-06 | 5.015 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.060291e-05 | 4.975 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.122696e-05 | 4.950 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 1.186122e-05 | 4.926 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.187654e-05 | 4.925 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 1.250459e-05 | 4.903 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 1.396697e-05 | 4.855 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 1.340871e-05 | 4.873 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.519374e-05 | 4.818 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.519374e-05 | 4.818 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.579972e-05 | 4.801 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.635723e-05 | 4.786 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 1.670055e-05 | 4.777 | 0 | 0 |
| Depurination | R-HSA-73927 | 1.754090e-05 | 4.756 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.855586e-05 | 4.544 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 3.599252e-05 | 4.444 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 4.293811e-05 | 4.367 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 4.293811e-05 | 4.367 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 4.876314e-05 | 4.312 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 4.876314e-05 | 4.312 | 0 | 0 |
| Translation | R-HSA-72766 | 4.529601e-05 | 4.344 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 4.965989e-05 | 4.304 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 5.358310e-05 | 4.271 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 5.759420e-05 | 4.240 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 5.971405e-05 | 4.224 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 6.011478e-05 | 4.221 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 6.011478e-05 | 4.221 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 8.218082e-05 | 4.085 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.036689e-04 | 3.984 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 1.246013e-04 | 3.904 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 1.396893e-04 | 3.855 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.318395e-04 | 3.880 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 1.397756e-04 | 3.855 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 1.433338e-04 | 3.844 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 1.934055e-04 | 3.714 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.984909e-04 | 3.702 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 2.458087e-04 | 3.609 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 2.483417e-04 | 3.605 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.546380e-04 | 3.594 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 2.658601e-04 | 3.575 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 3.099009e-04 | 3.509 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 3.122488e-04 | 3.505 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 3.444657e-04 | 3.463 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 3.618349e-04 | 3.441 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 3.758720e-04 | 3.425 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 3.795988e-04 | 3.421 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 3.969702e-04 | 3.401 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 4.228954e-04 | 3.374 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 4.351367e-04 | 3.361 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 4.613904e-04 | 3.336 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 4.878241e-04 | 3.312 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 4.935623e-04 | 3.307 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 4.750585e-04 | 3.323 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 4.675719e-04 | 3.330 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 5.245643e-04 | 3.280 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 5.747146e-04 | 3.241 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 5.773910e-04 | 3.239 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 5.939215e-04 | 3.226 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 6.345404e-04 | 3.198 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 6.367252e-04 | 3.196 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 7.276689e-04 | 3.138 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 7.277132e-04 | 3.138 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 7.420728e-04 | 3.130 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 7.420728e-04 | 3.130 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 7.420728e-04 | 3.130 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 7.516408e-04 | 3.124 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 7.516408e-04 | 3.124 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 7.608455e-04 | 3.119 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 7.608455e-04 | 3.119 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 8.332461e-04 | 3.079 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 8.727886e-04 | 3.059 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 8.656114e-04 | 3.063 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 8.727886e-04 | 3.059 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 9.250811e-04 | 3.034 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 9.585834e-04 | 3.018 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 9.703010e-04 | 3.013 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 9.832415e-04 | 3.007 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 9.832415e-04 | 3.007 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 9.832415e-04 | 3.007 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 9.924620e-04 | 3.003 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.023757e-03 | 2.990 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.025748e-03 | 2.989 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 1.031487e-03 | 2.987 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.066675e-03 | 2.972 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.071973e-03 | 2.970 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.143028e-03 | 2.942 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.167138e-03 | 2.933 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.221205e-03 | 2.913 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.326439e-03 | 2.877 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 1.361534e-03 | 2.866 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 1.399369e-03 | 2.854 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 1.399369e-03 | 2.854 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 1.445067e-03 | 2.840 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.445067e-03 | 2.840 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.445067e-03 | 2.840 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 1.470201e-03 | 2.833 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.515893e-03 | 2.819 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 1.522354e-03 | 2.817 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 1.522354e-03 | 2.817 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.522354e-03 | 2.817 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 1.542835e-03 | 2.812 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.542835e-03 | 2.812 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 1.630775e-03 | 2.788 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.605772e-03 | 2.794 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 1.783398e-03 | 2.749 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 1.783398e-03 | 2.749 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 1.839511e-03 | 2.735 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 1.994417e-03 | 2.700 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 2.079202e-03 | 2.682 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 2.115079e-03 | 2.675 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 2.122638e-03 | 2.673 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 2.142015e-03 | 2.669 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 2.163911e-03 | 2.665 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 2.172723e-03 | 2.663 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 2.219567e-03 | 2.654 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 2.247125e-03 | 2.648 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 2.269697e-03 | 2.644 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 2.309858e-03 | 2.636 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 2.471270e-03 | 2.607 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 2.619241e-03 | 2.582 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 2.625004e-03 | 2.581 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.672700e-03 | 2.573 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 2.707658e-03 | 2.567 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 2.758643e-03 | 2.559 | 0 | 0 |
| S Phase | R-HSA-69242 | 3.060755e-03 | 2.514 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 3.078584e-03 | 2.512 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 3.111667e-03 | 2.507 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 3.138996e-03 | 2.503 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 3.245254e-03 | 2.489 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 3.245254e-03 | 2.489 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 3.261371e-03 | 2.487 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 3.261371e-03 | 2.487 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 3.324868e-03 | 2.478 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 3.511598e-03 | 2.454 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 3.555706e-03 | 2.449 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 3.633648e-03 | 2.440 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 3.633648e-03 | 2.440 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 3.720749e-03 | 2.429 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 3.761385e-03 | 2.425 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 4.303718e-03 | 2.366 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 3.768310e-03 | 2.424 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 4.294990e-03 | 2.367 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 4.465425e-03 | 2.350 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 4.465425e-03 | 2.350 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 4.227679e-03 | 2.374 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 3.796559e-03 | 2.421 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 3.741459e-03 | 2.427 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 4.512560e-03 | 2.346 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 4.711823e-03 | 2.327 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 4.874892e-03 | 2.312 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 5.023669e-03 | 2.299 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 5.187850e-03 | 2.285 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 5.219820e-03 | 2.282 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 5.219820e-03 | 2.282 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 5.219820e-03 | 2.282 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 5.219820e-03 | 2.282 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 5.222693e-03 | 2.282 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 5.224897e-03 | 2.282 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 5.270280e-03 | 2.278 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 5.672663e-03 | 2.246 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 5.764380e-03 | 2.239 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 5.871661e-03 | 2.231 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 6.244478e-03 | 2.205 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 6.426387e-03 | 2.192 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 6.431100e-03 | 2.192 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 6.548726e-03 | 2.184 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 6.638542e-03 | 2.178 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 6.750125e-03 | 2.171 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 6.750125e-03 | 2.171 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 6.750125e-03 | 2.171 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 7.082210e-03 | 2.150 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 7.221079e-03 | 2.141 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 7.445339e-03 | 2.128 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 7.593593e-03 | 2.120 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 7.641169e-03 | 2.117 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 7.772912e-03 | 2.109 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 7.772912e-03 | 2.109 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 9.922419e-03 | 2.003 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 8.894829e-03 | 2.051 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 8.894829e-03 | 2.051 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 8.917835e-03 | 2.050 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 8.913294e-03 | 2.050 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 8.122999e-03 | 2.090 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 9.484572e-03 | 2.023 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 9.693908e-03 | 2.014 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 8.789506e-03 | 2.056 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 8.325834e-03 | 2.080 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 9.366353e-03 | 2.028 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 8.793207e-03 | 2.056 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 9.070708e-03 | 2.042 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 8.205778e-03 | 2.086 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 9.386782e-03 | 2.027 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 9.411173e-03 | 2.026 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 8.917835e-03 | 2.050 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 9.046134e-03 | 2.044 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 8.894829e-03 | 2.051 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 8.913294e-03 | 2.050 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 9.302771e-03 | 2.031 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 8.282678e-03 | 2.082 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 8.325834e-03 | 2.080 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 9.693908e-03 | 2.014 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 8.789506e-03 | 2.056 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 8.789506e-03 | 2.056 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 1.017991e-02 | 1.992 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 1.017991e-02 | 1.992 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 1.025845e-02 | 1.989 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.025845e-02 | 1.989 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.025845e-02 | 1.989 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.025845e-02 | 1.989 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 1.041202e-02 | 1.982 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 1.043636e-02 | 1.981 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.043636e-02 | 1.981 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 1.051450e-02 | 1.978 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 1.098112e-02 | 1.959 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 1.102617e-02 | 1.958 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 1.102617e-02 | 1.958 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 1.115209e-02 | 1.953 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 1.136406e-02 | 1.944 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 1.147974e-02 | 1.940 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.157340e-02 | 1.937 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 1.177396e-02 | 1.929 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 1.177583e-02 | 1.929 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 1.208915e-02 | 1.918 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 1.265041e-02 | 1.898 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 1.265041e-02 | 1.898 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.265041e-02 | 1.898 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.265041e-02 | 1.898 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 1.277224e-02 | 1.894 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.277224e-02 | 1.894 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 1.284734e-02 | 1.891 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 1.284734e-02 | 1.891 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 1.303903e-02 | 1.885 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 1.312699e-02 | 1.882 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 1.327762e-02 | 1.877 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 1.355206e-02 | 1.868 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.372442e-02 | 1.863 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 1.372442e-02 | 1.863 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 1.391865e-02 | 1.856 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 1.396228e-02 | 1.855 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 1.474549e-02 | 1.831 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 1.474549e-02 | 1.831 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 1.515461e-02 | 1.819 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.586531e-02 | 1.800 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 1.586531e-02 | 1.800 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 1.586531e-02 | 1.800 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 1.595127e-02 | 1.797 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 1.595127e-02 | 1.797 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.635997e-02 | 1.786 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.635997e-02 | 1.786 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 1.635997e-02 | 1.786 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.722521e-02 | 1.764 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.722521e-02 | 1.764 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.722521e-02 | 1.764 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.722521e-02 | 1.764 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.722521e-02 | 1.764 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 1.722521e-02 | 1.764 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 1.841093e-02 | 1.735 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 1.841093e-02 | 1.735 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 1.961722e-02 | 1.707 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 1.748942e-02 | 1.757 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 2.018071e-02 | 1.695 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 1.834821e-02 | 1.736 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 1.871536e-02 | 1.728 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 2.092488e-02 | 1.679 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 2.092488e-02 | 1.679 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 1.960455e-02 | 1.708 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 1.790205e-02 | 1.747 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.790205e-02 | 1.747 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 2.191150e-02 | 1.659 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 2.120351e-02 | 1.674 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 1.834821e-02 | 1.736 | 0 | 0 |
| Kinesins | R-HSA-983189 | 2.051493e-02 | 1.688 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.988699e-02 | 1.701 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 1.790205e-02 | 1.747 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 2.088638e-02 | 1.680 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 1.834821e-02 | 1.736 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.868904e-02 | 1.728 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 2.018071e-02 | 1.695 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 2.256666e-02 | 1.647 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 2.284255e-02 | 1.641 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 2.284255e-02 | 1.641 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 2.284255e-02 | 1.641 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 2.284255e-02 | 1.641 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 2.284255e-02 | 1.641 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 2.315856e-02 | 1.635 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 2.315856e-02 | 1.635 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 2.315856e-02 | 1.635 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 2.330206e-02 | 1.633 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 2.367106e-02 | 1.626 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 2.367106e-02 | 1.626 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 2.379178e-02 | 1.624 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.390219e-02 | 1.622 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 2.394360e-02 | 1.621 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 2.497922e-02 | 1.602 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 2.497922e-02 | 1.602 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 2.497922e-02 | 1.602 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 2.497922e-02 | 1.602 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 2.497922e-02 | 1.602 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 2.497922e-02 | 1.602 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 2.512076e-02 | 1.600 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 2.541593e-02 | 1.595 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 2.541593e-02 | 1.595 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 2.541593e-02 | 1.595 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 2.541593e-02 | 1.595 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 2.541593e-02 | 1.595 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 2.591570e-02 | 1.586 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.599274e-02 | 1.585 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 2.643743e-02 | 1.578 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 2.643743e-02 | 1.578 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 2.654146e-02 | 1.576 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.654146e-02 | 1.576 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 2.743767e-02 | 1.562 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 2.858871e-02 | 1.544 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 2.858871e-02 | 1.544 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 2.871355e-02 | 1.542 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 2.871355e-02 | 1.542 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 2.878848e-02 | 1.541 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 2.953090e-02 | 1.530 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 2.953090e-02 | 1.530 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 3.002652e-02 | 1.522 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 3.003101e-02 | 1.522 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 3.003101e-02 | 1.522 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 3.176629e-02 | 1.498 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 3.184149e-02 | 1.497 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.204502e-02 | 1.494 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 3.279437e-02 | 1.484 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 3.279437e-02 | 1.484 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 3.279437e-02 | 1.484 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 3.279437e-02 | 1.484 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 3.279437e-02 | 1.484 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 3.281936e-02 | 1.484 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 3.335551e-02 | 1.477 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 3.355978e-02 | 1.474 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 3.361918e-02 | 1.473 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 3.395208e-02 | 1.469 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 3.395208e-02 | 1.469 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 3.395208e-02 | 1.469 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 3.428942e-02 | 1.465 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 3.450788e-02 | 1.462 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 3.502300e-02 | 1.456 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 3.517439e-02 | 1.454 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 3.517439e-02 | 1.454 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 3.517439e-02 | 1.454 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 3.517439e-02 | 1.454 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.633161e-02 | 1.440 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 3.714263e-02 | 1.430 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 3.714263e-02 | 1.430 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.714263e-02 | 1.430 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 3.822951e-02 | 1.418 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 4.015803e-02 | 1.396 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 4.015803e-02 | 1.396 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 4.042648e-02 | 1.393 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 4.042648e-02 | 1.393 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 4.042648e-02 | 1.393 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 4.042648e-02 | 1.393 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 4.042648e-02 | 1.393 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 4.042648e-02 | 1.393 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 4.073958e-02 | 1.390 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 6.058206e-02 | 1.218 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 6.058206e-02 | 1.218 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 6.058206e-02 | 1.218 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 6.058206e-02 | 1.218 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 6.058206e-02 | 1.218 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 6.058206e-02 | 1.218 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 6.058206e-02 | 1.218 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 6.058206e-02 | 1.218 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 6.058206e-02 | 1.218 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 6.058206e-02 | 1.218 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 6.058206e-02 | 1.218 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 6.058206e-02 | 1.218 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 6.058206e-02 | 1.218 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 6.058206e-02 | 1.218 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 4.636389e-02 | 1.334 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 4.636389e-02 | 1.334 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 4.188418e-02 | 1.378 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 4.262425e-02 | 1.370 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 4.262425e-02 | 1.370 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 4.262425e-02 | 1.370 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 5.095370e-02 | 1.293 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 6.016907e-02 | 1.221 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 5.467105e-02 | 1.262 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 5.467105e-02 | 1.262 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 4.886938e-02 | 1.311 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 4.331530e-02 | 1.363 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 4.779231e-02 | 1.321 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 4.274639e-02 | 1.369 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 4.520031e-02 | 1.345 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 6.004692e-02 | 1.222 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 4.372495e-02 | 1.359 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 4.372495e-02 | 1.359 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 4.721641e-02 | 1.326 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 6.004692e-02 | 1.222 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 6.116902e-02 | 1.213 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 5.312957e-02 | 1.275 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 4.372495e-02 | 1.359 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 6.016907e-02 | 1.221 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 4.094917e-02 | 1.388 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 5.312957e-02 | 1.275 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 5.534327e-02 | 1.257 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 5.550233e-02 | 1.256 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 5.550233e-02 | 1.256 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 5.884132e-02 | 1.230 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 4.636389e-02 | 1.334 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 4.886938e-02 | 1.311 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 5.884132e-02 | 1.230 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 4.165331e-02 | 1.380 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 5.477695e-02 | 1.261 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 4.570258e-02 | 1.340 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 6.116902e-02 | 1.213 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 6.116902e-02 | 1.213 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 6.026570e-02 | 1.220 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 4.331530e-02 | 1.363 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 4.168401e-02 | 1.380 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 5.477695e-02 | 1.261 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 4.439033e-02 | 1.353 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 4.168401e-02 | 1.380 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 4.372495e-02 | 1.359 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 4.588043e-02 | 1.338 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 5.550233e-02 | 1.256 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 4.168401e-02 | 1.380 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 4.274639e-02 | 1.369 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 4.210030e-02 | 1.376 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.210030e-02 | 1.376 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 5.225516e-02 | 1.282 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 4.231152e-02 | 1.374 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 4.779231e-02 | 1.321 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 4.813320e-02 | 1.318 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 5.463279e-02 | 1.263 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 5.463279e-02 | 1.263 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 5.095370e-02 | 1.293 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 5.312957e-02 | 1.275 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 4.188418e-02 | 1.378 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 5.808637e-02 | 1.236 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 6.149685e-02 | 1.211 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 6.271081e-02 | 1.203 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 6.279739e-02 | 1.202 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 6.378293e-02 | 1.195 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 6.456545e-02 | 1.190 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 6.493303e-02 | 1.188 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 6.493303e-02 | 1.188 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 6.580466e-02 | 1.182 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 6.580466e-02 | 1.182 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 6.723305e-02 | 1.172 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 6.876032e-02 | 1.163 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 7.044062e-02 | 1.152 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 7.140877e-02 | 1.146 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 7.140877e-02 | 1.146 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 7.159752e-02 | 1.145 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 7.159752e-02 | 1.145 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 7.346496e-02 | 1.134 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 7.346496e-02 | 1.134 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 7.530120e-02 | 1.123 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 7.677166e-02 | 1.115 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 7.677166e-02 | 1.115 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 7.677166e-02 | 1.115 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 7.677166e-02 | 1.115 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 7.677166e-02 | 1.115 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 7.677166e-02 | 1.115 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 7.677166e-02 | 1.115 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 7.827116e-02 | 1.106 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 7.861809e-02 | 1.104 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 7.861809e-02 | 1.104 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 7.861809e-02 | 1.104 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 7.864985e-02 | 1.104 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 7.992319e-02 | 1.097 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 8.008033e-02 | 1.096 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 8.063675e-02 | 1.093 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 8.063675e-02 | 1.093 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 8.063675e-02 | 1.093 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 8.063675e-02 | 1.093 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 8.063675e-02 | 1.093 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 8.106876e-02 | 1.091 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 8.106876e-02 | 1.091 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 8.106876e-02 | 1.091 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 8.123949e-02 | 1.090 | 0 | 0 |
| PKA activation | R-HSA-163615 | 8.123949e-02 | 1.090 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 8.123949e-02 | 1.090 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 8.177355e-02 | 1.087 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 8.285874e-02 | 1.082 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 8.374035e-02 | 1.077 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 8.552133e-02 | 1.068 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 8.552133e-02 | 1.068 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 8.552133e-02 | 1.068 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 8.552133e-02 | 1.068 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 8.552133e-02 | 1.068 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 8.702099e-02 | 1.060 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 8.702099e-02 | 1.060 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 8.752429e-02 | 1.058 | 0 | 0 |
| Protein folding | R-HSA-391251 | 8.860986e-02 | 1.053 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 8.883681e-02 | 1.051 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 8.883681e-02 | 1.051 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 8.883681e-02 | 1.051 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 9.084153e-02 | 1.042 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 9.084153e-02 | 1.042 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 9.084153e-02 | 1.042 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 9.120385e-02 | 1.040 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 9.124117e-02 | 1.040 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.124117e-02 | 1.040 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 9.295809e-02 | 1.032 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 9.306531e-02 | 1.031 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 9.436149e-02 | 1.025 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 9.436149e-02 | 1.025 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 9.436149e-02 | 1.025 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 9.436149e-02 | 1.025 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 9.436149e-02 | 1.025 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 9.436149e-02 | 1.025 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 9.436149e-02 | 1.025 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 9.436149e-02 | 1.025 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 9.436149e-02 | 1.025 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 9.436149e-02 | 1.025 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 9.436149e-02 | 1.025 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 9.480392e-02 | 1.023 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 9.610526e-02 | 1.017 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 9.687157e-02 | 1.014 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 9.687157e-02 | 1.014 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 9.687157e-02 | 1.014 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 9.714687e-02 | 1.013 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 9.731350e-02 | 1.012 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 9.756227e-02 | 1.011 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 9.756227e-02 | 1.011 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 9.950727e-02 | 1.002 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 9.988534e-02 | 1.000 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.000684e-01 | 1.000 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 1.019911e-01 | 0.991 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 1.026938e-01 | 0.988 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 1.043413e-01 | 0.982 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 1.060458e-01 | 0.975 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 1.067466e-01 | 0.972 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.087335e-01 | 0.964 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 1.091407e-01 | 0.962 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 1.091407e-01 | 0.962 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 1.091407e-01 | 0.962 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 1.134147e-01 | 0.945 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 1.134147e-01 | 0.945 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 1.134147e-01 | 0.945 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 1.134147e-01 | 0.945 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 1.134147e-01 | 0.945 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 1.169353e-01 | 0.932 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 1.171392e-01 | 0.931 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 1.171392e-01 | 0.931 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 1.180329e-01 | 0.928 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 1.180593e-01 | 0.928 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 1.181451e-01 | 0.928 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.181451e-01 | 0.928 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.181451e-01 | 0.928 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 1.181451e-01 | 0.928 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 1.191710e-01 | 0.924 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 1.191710e-01 | 0.924 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 1.191710e-01 | 0.924 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 1.191710e-01 | 0.924 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 1.191710e-01 | 0.924 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 1.191710e-01 | 0.924 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 1.201252e-01 | 0.920 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 1.201252e-01 | 0.920 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 1.201252e-01 | 0.920 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 1.201252e-01 | 0.920 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 1.201252e-01 | 0.920 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.219373e-01 | 0.914 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 1.223154e-01 | 0.913 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 1.223154e-01 | 0.913 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 1.223154e-01 | 0.913 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 1.223154e-01 | 0.913 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.245674e-01 | 0.905 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 1.254549e-01 | 0.902 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 1.257555e-01 | 0.900 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 1.283871e-01 | 0.891 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 1.798239e-01 | 0.745 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 1.798239e-01 | 0.745 | 0 | 0 |
| RPIA deficiency: failed conversion of RU5P to R5P | R-HSA-6791461 | 1.798239e-01 | 0.745 | 0 | 0 |
| RPIA deficiency: failed conversion of R5P to RU5P | R-HSA-5659996 | 1.798239e-01 | 0.745 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 2.572261e-01 | 0.590 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 2.572261e-01 | 0.590 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 2.572261e-01 | 0.590 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 2.572261e-01 | 0.590 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 2.572261e-01 | 0.590 | 0 | 0 |
| Defective MMADHC causes MMAHCD | R-HSA-3359473 | 2.572261e-01 | 0.590 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 2.572261e-01 | 0.590 | 0 | 0 |
| Mitochondrial short-chain enoyl-CoA hydratase deficiency 1 | R-HSA-9916720 | 2.572261e-01 | 0.590 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 2.572261e-01 | 0.590 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 1.536240e-01 | 0.814 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.536240e-01 | 0.814 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 1.536240e-01 | 0.814 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 1.886380e-01 | 0.724 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 1.886380e-01 | 0.724 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 1.886380e-01 | 0.724 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 1.886380e-01 | 0.724 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.401715e-01 | 0.853 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 1.401715e-01 | 0.853 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 2.245835e-01 | 0.649 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 2.245835e-01 | 0.649 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 1.395728e-01 | 0.855 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 1.877571e-01 | 0.726 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 2.609732e-01 | 0.583 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 2.609732e-01 | 0.583 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 2.609732e-01 | 0.583 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 2.609732e-01 | 0.583 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 2.609732e-01 | 0.583 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 1.577341e-01 | 0.802 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 1.577341e-01 | 0.802 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 2.129232e-01 | 0.672 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 2.129232e-01 | 0.672 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 2.129232e-01 | 0.672 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 1.333812e-01 | 0.875 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 2.387532e-01 | 0.622 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 1.964094e-01 | 0.707 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 1.801208e-01 | 0.744 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 1.650281e-01 | 0.782 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.969039e-01 | 0.706 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 2.141990e-01 | 0.669 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 2.589098e-01 | 0.587 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 1.894806e-01 | 0.722 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 1.894806e-01 | 0.722 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 1.723010e-01 | 0.764 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 2.384628e-01 | 0.623 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 2.388129e-01 | 0.622 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 2.282242e-01 | 0.642 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 2.456375e-01 | 0.610 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 1.635913e-01 | 0.786 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 2.387532e-01 | 0.622 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.512895e-01 | 0.820 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 1.792728e-01 | 0.746 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 1.877571e-01 | 0.726 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 2.129232e-01 | 0.672 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 1.571417e-01 | 0.804 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 1.536240e-01 | 0.814 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 1.964464e-01 | 0.707 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 1.601158e-01 | 0.796 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 2.129232e-01 | 0.672 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 1.650281e-01 | 0.782 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 2.589098e-01 | 0.587 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 1.483080e-01 | 0.829 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 1.307118e-01 | 0.884 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 1.574120e-01 | 0.803 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 2.085631e-01 | 0.681 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 1.536240e-01 | 0.814 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 1.512895e-01 | 0.820 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 1.607590e-01 | 0.794 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 1.577341e-01 | 0.802 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 2.129232e-01 | 0.672 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 2.311177e-01 | 0.636 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 1.785751e-01 | 0.748 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 1.886380e-01 | 0.724 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 1.886380e-01 | 0.724 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 2.250361e-01 | 0.648 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 1.495931e-01 | 0.825 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 1.495931e-01 | 0.825 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 1.842028e-01 | 0.735 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 1.703017e-01 | 0.769 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 1.316062e-01 | 0.881 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 1.577341e-01 | 0.802 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 1.530852e-01 | 0.815 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 2.177181e-01 | 0.662 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 1.884186e-01 | 0.725 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 1.624516e-01 | 0.789 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.399859e-01 | 0.854 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 2.502098e-01 | 0.602 | 0 | 0 |
| SDK interactions | R-HSA-373756 | 1.798239e-01 | 0.745 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 2.572261e-01 | 0.590 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 2.572261e-01 | 0.590 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 2.572261e-01 | 0.590 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 1.395728e-01 | 0.855 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 2.609732e-01 | 0.583 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 1.767102e-01 | 0.753 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 2.387532e-01 | 0.622 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 1.964094e-01 | 0.707 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 1.723010e-01 | 0.764 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 2.604155e-01 | 0.584 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.505923e-01 | 0.601 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 1.571417e-01 | 0.804 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 1.614755e-01 | 0.792 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 2.079087e-01 | 0.682 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 1.577341e-01 | 0.802 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 2.228359e-01 | 0.652 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 1.530852e-01 | 0.815 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 2.228359e-01 | 0.652 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 1.913175e-01 | 0.718 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 1.939897e-01 | 0.712 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 1.939897e-01 | 0.712 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 1.897625e-01 | 0.722 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 2.609732e-01 | 0.583 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 1.936963e-01 | 0.713 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 2.500997e-01 | 0.602 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 1.828300e-01 | 0.738 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 1.483080e-01 | 0.829 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 2.572261e-01 | 0.590 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 2.245835e-01 | 0.649 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 1.964094e-01 | 0.707 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.792728e-01 | 0.746 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 1.370459e-01 | 0.863 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 2.456375e-01 | 0.610 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 2.406104e-01 | 0.619 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 1.333812e-01 | 0.875 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.030118e-01 | 0.692 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 1.578061e-01 | 0.802 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 1.769776e-01 | 0.752 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 2.406104e-01 | 0.619 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 1.400606e-01 | 0.854 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 1.453044e-01 | 0.838 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 2.114500e-01 | 0.675 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 1.381921e-01 | 0.860 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 1.469209e-01 | 0.833 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 2.491097e-01 | 0.604 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 2.388129e-01 | 0.622 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 1.401715e-01 | 0.853 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 2.500997e-01 | 0.602 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 2.609732e-01 | 0.583 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 1.577341e-01 | 0.802 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 2.589098e-01 | 0.587 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 1.969039e-01 | 0.706 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 1.558945e-01 | 0.807 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 2.088261e-01 | 0.680 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 1.395728e-01 | 0.855 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 1.767102e-01 | 0.753 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 2.376024e-01 | 0.624 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 2.650701e-01 | 0.577 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 2.650701e-01 | 0.577 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 2.650701e-01 | 0.577 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 2.650701e-01 | 0.577 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 2.666758e-01 | 0.574 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.805691e-01 | 0.552 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 2.805691e-01 | 0.552 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 2.805691e-01 | 0.552 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 2.818444e-01 | 0.550 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 2.895361e-01 | 0.538 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 2.895361e-01 | 0.538 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 2.895361e-01 | 0.538 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 2.895361e-01 | 0.538 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 2.901300e-01 | 0.537 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 2.901300e-01 | 0.537 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 2.907218e-01 | 0.537 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 2.907218e-01 | 0.537 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 2.917080e-01 | 0.535 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 2.917080e-01 | 0.535 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 2.917080e-01 | 0.535 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 2.927517e-01 | 0.534 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 2.974037e-01 | 0.527 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 2.974037e-01 | 0.527 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 2.974037e-01 | 0.527 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 2.981443e-01 | 0.526 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 2.989949e-01 | 0.524 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 3.024921e-01 | 0.519 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 3.042722e-01 | 0.517 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 3.042722e-01 | 0.517 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 3.061606e-01 | 0.514 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 3.063720e-01 | 0.514 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 3.063720e-01 | 0.514 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 3.068320e-01 | 0.513 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 3.070973e-01 | 0.513 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 3.070973e-01 | 0.513 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 3.170304e-01 | 0.499 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 3.172758e-01 | 0.499 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 3.185134e-01 | 0.497 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 3.185134e-01 | 0.497 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 3.185134e-01 | 0.497 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 3.217559e-01 | 0.492 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 3.227776e-01 | 0.491 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 3.245941e-01 | 0.489 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 3.245941e-01 | 0.489 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 3.245941e-01 | 0.489 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 3.255502e-01 | 0.487 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 3.273278e-01 | 0.485 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 3.273278e-01 | 0.485 | 0 | 0 |
| Defective AHCY causes HMAHCHD | R-HSA-5578997 | 3.273278e-01 | 0.485 | 0 | 0 |
| Signalling to ERK5 | R-HSA-198765 | 3.273278e-01 | 0.485 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 3.273278e-01 | 0.485 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 3.329563e-01 | 0.478 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 3.335433e-01 | 0.477 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 3.335433e-01 | 0.477 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 3.335433e-01 | 0.477 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 3.335433e-01 | 0.477 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 3.335433e-01 | 0.477 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 3.335433e-01 | 0.477 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 3.335433e-01 | 0.477 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 3.335433e-01 | 0.477 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 3.335433e-01 | 0.477 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 3.414886e-01 | 0.467 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 3.414886e-01 | 0.467 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 3.423495e-01 | 0.466 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 3.435396e-01 | 0.464 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 3.448484e-01 | 0.462 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 3.448484e-01 | 0.462 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 3.448484e-01 | 0.462 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 3.453454e-01 | 0.462 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 3.453454e-01 | 0.462 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 3.467940e-01 | 0.460 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 3.467940e-01 | 0.460 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 3.467940e-01 | 0.460 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 3.467940e-01 | 0.460 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 3.477777e-01 | 0.459 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 3.500706e-01 | 0.456 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 3.532992e-01 | 0.452 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 3.598506e-01 | 0.444 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 3.671332e-01 | 0.435 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 3.686271e-01 | 0.433 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 3.690155e-01 | 0.433 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 3.690155e-01 | 0.433 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 3.691228e-01 | 0.433 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 3.691228e-01 | 0.433 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 3.691228e-01 | 0.433 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 3.691228e-01 | 0.433 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 3.691228e-01 | 0.433 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 3.691228e-01 | 0.433 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 3.691228e-01 | 0.433 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 3.691228e-01 | 0.433 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 3.717091e-01 | 0.430 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 3.720762e-01 | 0.429 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 3.720762e-01 | 0.429 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 3.720762e-01 | 0.429 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 3.720762e-01 | 0.429 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 3.720762e-01 | 0.429 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 3.836002e-01 | 0.416 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 3.836002e-01 | 0.416 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 3.836002e-01 | 0.416 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 3.836002e-01 | 0.416 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 3.836002e-01 | 0.416 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 3.836002e-01 | 0.416 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 3.889513e-01 | 0.410 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 3.908171e-01 | 0.408 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 3.908171e-01 | 0.408 | 0 | 0 |
| Defective MMACHC causes MAHCC | R-HSA-3359474 | 3.908171e-01 | 0.408 | 0 | 0 |
| Defective ABCA1 causes TGD | R-HSA-5682113 | 3.908171e-01 | 0.408 | 0 | 0 |
| Defective SLC7A7 causes lysinuric protein intolerance (LPI) | R-HSA-5660862 | 3.908171e-01 | 0.408 | 0 | 0 |
| Adrenaline signalling through Alpha-2 adrenergic receptor | R-HSA-392023 | 3.908171e-01 | 0.408 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 3.908171e-01 | 0.408 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 3.908171e-01 | 0.408 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 3.911868e-01 | 0.408 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 3.911868e-01 | 0.408 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 3.911868e-01 | 0.408 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 3.911868e-01 | 0.408 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 3.920042e-01 | 0.407 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 3.933912e-01 | 0.405 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 3.936534e-01 | 0.405 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 3.975121e-01 | 0.401 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 3.985909e-01 | 0.399 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 3.985909e-01 | 0.399 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 3.985909e-01 | 0.399 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 4.001470e-01 | 0.398 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 4.039260e-01 | 0.394 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 4.039260e-01 | 0.394 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 4.039260e-01 | 0.394 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 4.039260e-01 | 0.394 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 4.039260e-01 | 0.394 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 4.039260e-01 | 0.394 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 4.039260e-01 | 0.394 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 4.039260e-01 | 0.394 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 4.110526e-01 | 0.386 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 4.113803e-01 | 0.386 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 4.132410e-01 | 0.384 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 4.132410e-01 | 0.384 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 4.132410e-01 | 0.384 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 4.132410e-01 | 0.384 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 4.132410e-01 | 0.384 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 4.132410e-01 | 0.384 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 4.222396e-01 | 0.374 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 4.247872e-01 | 0.372 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 4.247872e-01 | 0.372 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 4.247872e-01 | 0.372 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 4.247872e-01 | 0.372 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 4.247872e-01 | 0.372 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 4.252445e-01 | 0.371 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 4.327752e-01 | 0.364 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 4.346867e-01 | 0.362 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 4.351164e-01 | 0.361 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 4.377827e-01 | 0.359 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 4.377827e-01 | 0.359 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 4.377827e-01 | 0.359 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 4.377827e-01 | 0.359 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 4.377827e-01 | 0.359 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 4.377827e-01 | 0.359 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 4.377827e-01 | 0.359 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 4.443457e-01 | 0.352 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 4.456687e-01 | 0.351 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 4.470265e-01 | 0.350 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 4.470265e-01 | 0.350 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 4.483175e-01 | 0.348 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 4.483175e-01 | 0.348 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 4.483175e-01 | 0.348 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 4.483175e-01 | 0.348 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 4.483175e-01 | 0.348 | 0 | 0 |
| Alanine metabolism | R-HSA-8964540 | 4.483175e-01 | 0.348 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 4.483175e-01 | 0.348 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 4.483175e-01 | 0.348 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 4.483175e-01 | 0.348 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 4.483175e-01 | 0.348 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 4.505751e-01 | 0.346 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 4.505751e-01 | 0.346 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 4.505751e-01 | 0.346 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 4.505751e-01 | 0.346 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 4.505751e-01 | 0.346 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 4.505751e-01 | 0.346 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 4.505751e-01 | 0.346 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 4.505751e-01 | 0.346 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 4.505751e-01 | 0.346 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 4.505751e-01 | 0.346 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 4.543410e-01 | 0.343 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 4.567564e-01 | 0.340 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 4.567564e-01 | 0.340 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 4.567564e-01 | 0.340 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 4.645080e-01 | 0.333 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 4.705616e-01 | 0.327 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 4.705616e-01 | 0.327 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 4.705616e-01 | 0.327 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 4.705616e-01 | 0.327 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 4.705616e-01 | 0.327 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 4.705616e-01 | 0.327 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 4.705616e-01 | 0.327 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 4.705616e-01 | 0.327 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 4.705616e-01 | 0.327 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 4.758764e-01 | 0.323 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 4.758764e-01 | 0.323 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 4.781093e-01 | 0.320 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 4.781093e-01 | 0.320 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 4.781093e-01 | 0.320 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 4.781093e-01 | 0.320 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 4.781093e-01 | 0.320 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 4.781093e-01 | 0.320 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 4.792363e-01 | 0.319 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 4.792363e-01 | 0.319 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 4.797110e-01 | 0.319 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 4.797110e-01 | 0.319 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 4.798409e-01 | 0.319 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 4.798409e-01 | 0.319 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 4.939375e-01 | 0.306 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 4.956815e-01 | 0.305 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 4.956815e-01 | 0.305 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 4.966914e-01 | 0.304 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 4.966914e-01 | 0.304 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 4.978282e-01 | 0.303 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 4.978282e-01 | 0.303 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 4.991288e-01 | 0.302 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 5.003936e-01 | 0.301 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 5.003936e-01 | 0.301 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 5.003936e-01 | 0.301 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 5.003936e-01 | 0.301 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.003936e-01 | 0.301 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 5.003936e-01 | 0.301 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 5.003936e-01 | 0.301 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 5.003936e-01 | 0.301 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 5.003936e-01 | 0.301 | 0 | 0 |
| Assembly of Viral Components at the Budding Site | R-HSA-168316 | 5.003936e-01 | 0.301 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 5.021646e-01 | 0.299 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 5.021646e-01 | 0.299 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 5.036681e-01 | 0.298 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 5.074440e-01 | 0.295 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 5.110572e-01 | 0.292 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 5.233369e-01 | 0.281 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 5.247601e-01 | 0.280 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 5.247601e-01 | 0.280 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 5.247601e-01 | 0.280 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 5.247601e-01 | 0.280 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 5.247601e-01 | 0.280 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 5.262670e-01 | 0.279 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 5.262670e-01 | 0.279 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 5.277506e-01 | 0.278 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 5.297983e-01 | 0.276 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 5.325216e-01 | 0.274 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 5.325216e-01 | 0.274 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 5.325216e-01 | 0.274 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 5.325216e-01 | 0.274 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 5.325216e-01 | 0.274 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 5.342095e-01 | 0.272 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 5.342095e-01 | 0.272 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 5.400065e-01 | 0.268 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 5.400065e-01 | 0.268 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 5.412932e-01 | 0.267 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 5.460108e-01 | 0.263 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 5.472528e-01 | 0.262 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 5.475567e-01 | 0.262 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 5.475567e-01 | 0.262 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 5.475567e-01 | 0.262 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 5.475567e-01 | 0.262 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 5.475567e-01 | 0.262 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 5.475567e-01 | 0.262 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 5.475567e-01 | 0.262 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 5.475567e-01 | 0.262 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.475567e-01 | 0.262 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 5.475567e-01 | 0.262 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 5.475567e-01 | 0.262 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 5.475567e-01 | 0.262 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 5.475567e-01 | 0.262 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 5.482383e-01 | 0.261 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 5.482383e-01 | 0.261 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 5.561190e-01 | 0.255 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 5.561195e-01 | 0.255 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 5.597960e-01 | 0.252 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 5.615863e-01 | 0.251 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 5.615863e-01 | 0.251 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 5.615863e-01 | 0.251 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 5.615863e-01 | 0.251 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 5.615863e-01 | 0.251 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 5.619697e-01 | 0.250 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 5.650416e-01 | 0.248 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 5.666076e-01 | 0.247 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 5.707309e-01 | 0.244 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 5.707309e-01 | 0.244 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.707309e-01 | 0.244 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 5.710199e-01 | 0.243 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 5.710199e-01 | 0.243 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 5.791142e-01 | 0.237 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 5.791142e-01 | 0.237 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 5.791142e-01 | 0.237 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 5.791142e-01 | 0.237 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 5.791142e-01 | 0.237 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 5.843106e-01 | 0.233 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 5.851136e-01 | 0.233 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 5.863871e-01 | 0.232 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 5.863871e-01 | 0.232 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 5.863871e-01 | 0.232 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 5.893322e-01 | 0.230 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 5.893322e-01 | 0.230 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 5.893322e-01 | 0.230 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 5.893322e-01 | 0.230 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 5.893322e-01 | 0.230 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 5.893322e-01 | 0.230 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 5.893322e-01 | 0.230 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 5.893322e-01 | 0.230 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 5.902701e-01 | 0.229 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 5.902701e-01 | 0.229 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 5.902701e-01 | 0.229 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 5.902701e-01 | 0.229 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 5.902701e-01 | 0.229 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 5.902701e-01 | 0.229 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 5.902701e-01 | 0.229 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 5.902701e-01 | 0.229 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 5.902701e-01 | 0.229 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 5.902701e-01 | 0.229 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 5.930747e-01 | 0.227 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 5.930747e-01 | 0.227 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 5.930747e-01 | 0.227 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 5.930747e-01 | 0.227 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 5.930747e-01 | 0.227 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 5.930747e-01 | 0.227 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 5.930747e-01 | 0.227 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 5.930747e-01 | 0.227 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 5.930747e-01 | 0.227 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 5.952182e-01 | 0.225 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 5.970940e-01 | 0.224 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 6.030564e-01 | 0.220 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 6.030564e-01 | 0.220 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 6.143798e-01 | 0.212 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 6.143798e-01 | 0.212 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 6.143798e-01 | 0.212 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 6.157492e-01 | 0.211 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 6.157492e-01 | 0.211 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 6.157492e-01 | 0.211 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 6.157492e-01 | 0.211 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 6.157492e-01 | 0.211 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 6.162477e-01 | 0.210 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 6.162477e-01 | 0.210 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 6.193361e-01 | 0.208 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 6.267680e-01 | 0.203 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 6.289534e-01 | 0.201 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 6.289534e-01 | 0.201 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 6.289534e-01 | 0.201 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 6.289534e-01 | 0.201 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 6.289534e-01 | 0.201 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 6.289534e-01 | 0.201 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 6.289534e-01 | 0.201 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 6.289534e-01 | 0.201 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 6.289534e-01 | 0.201 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 6.289534e-01 | 0.201 | 0 | 0 |
| Reuptake of GABA | R-HSA-888593 | 6.289534e-01 | 0.201 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 6.289534e-01 | 0.201 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 6.289534e-01 | 0.201 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 6.289534e-01 | 0.201 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 6.289534e-01 | 0.201 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 6.349191e-01 | 0.197 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 6.349191e-01 | 0.197 | 0 | 0 |
| Disease | R-HSA-1643685 | 6.351405e-01 | 0.197 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 6.352130e-01 | 0.197 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 6.396198e-01 | 0.194 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 6.408409e-01 | 0.193 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 6.408409e-01 | 0.193 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 6.408409e-01 | 0.193 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 6.408409e-01 | 0.193 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 6.506762e-01 | 0.187 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 6.512663e-01 | 0.186 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 6.546825e-01 | 0.184 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 6.546825e-01 | 0.184 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 6.546825e-01 | 0.184 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 6.639866e-01 | 0.178 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 6.639866e-01 | 0.178 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 6.639866e-01 | 0.178 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 6.639866e-01 | 0.178 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 6.639866e-01 | 0.178 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 6.639866e-01 | 0.178 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 6.639866e-01 | 0.178 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 6.639866e-01 | 0.178 | 0 | 0 |
| Fructose biosynthesis | R-HSA-5652227 | 6.639866e-01 | 0.178 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 6.639866e-01 | 0.178 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 6.639866e-01 | 0.178 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 6.639866e-01 | 0.178 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 6.639866e-01 | 0.178 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 6.639866e-01 | 0.178 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 6.646220e-01 | 0.177 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 6.646220e-01 | 0.177 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 6.646220e-01 | 0.177 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 6.646220e-01 | 0.177 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 6.646220e-01 | 0.177 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 6.646220e-01 | 0.177 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 6.646220e-01 | 0.177 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 6.646220e-01 | 0.177 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 6.646220e-01 | 0.177 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 6.646220e-01 | 0.177 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 6.653137e-01 | 0.177 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 6.688094e-01 | 0.175 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 6.736653e-01 | 0.172 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 6.736653e-01 | 0.172 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 6.736653e-01 | 0.172 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 6.736653e-01 | 0.172 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 6.736653e-01 | 0.172 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 6.784691e-01 | 0.168 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 6.840853e-01 | 0.165 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 6.840853e-01 | 0.165 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 6.840853e-01 | 0.165 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 6.871164e-01 | 0.163 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 6.871164e-01 | 0.163 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 6.871164e-01 | 0.163 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 6.871164e-01 | 0.163 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 6.918676e-01 | 0.160 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 6.957139e-01 | 0.158 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 6.957139e-01 | 0.158 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 6.957139e-01 | 0.158 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 6.957139e-01 | 0.158 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 6.957139e-01 | 0.158 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 6.957139e-01 | 0.158 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 6.957139e-01 | 0.158 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 6.957139e-01 | 0.158 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 6.957139e-01 | 0.158 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 6.957139e-01 | 0.158 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 6.957139e-01 | 0.158 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 6.957139e-01 | 0.158 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 7.083549e-01 | 0.150 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 7.083549e-01 | 0.150 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 7.083549e-01 | 0.150 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 7.092937e-01 | 0.149 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 7.141391e-01 | 0.146 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 7.146679e-01 | 0.146 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 7.244472e-01 | 0.140 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 7.244472e-01 | 0.140 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 7.244472e-01 | 0.140 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 7.244472e-01 | 0.140 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 7.244472e-01 | 0.140 | 0 | 0 |
| Sperm Motility And Taxes | R-HSA-1300642 | 7.244472e-01 | 0.140 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 7.244472e-01 | 0.140 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 7.244472e-01 | 0.140 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 7.259516e-01 | 0.139 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 7.259516e-01 | 0.139 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 7.283741e-01 | 0.138 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 7.283741e-01 | 0.138 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 7.283741e-01 | 0.138 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 7.283741e-01 | 0.138 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 7.291202e-01 | 0.137 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 7.291202e-01 | 0.137 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 7.304486e-01 | 0.136 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 7.418524e-01 | 0.130 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 7.418524e-01 | 0.130 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 7.418524e-01 | 0.130 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 7.418524e-01 | 0.130 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 7.472149e-01 | 0.127 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 7.472149e-01 | 0.127 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 7.472149e-01 | 0.127 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 7.504687e-01 | 0.125 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 7.504687e-01 | 0.125 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 7.504687e-01 | 0.125 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 7.504687e-01 | 0.125 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 7.504687e-01 | 0.125 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 7.504687e-01 | 0.125 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 7.504687e-01 | 0.125 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 7.504687e-01 | 0.125 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 7.520452e-01 | 0.124 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 7.570098e-01 | 0.121 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 7.570098e-01 | 0.121 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 7.570098e-01 | 0.121 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 7.573978e-01 | 0.121 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 7.618751e-01 | 0.118 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 7.649213e-01 | 0.116 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 7.649213e-01 | 0.116 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 7.649213e-01 | 0.116 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 7.649213e-01 | 0.116 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 7.649213e-01 | 0.116 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 7.649213e-01 | 0.116 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 7.688074e-01 | 0.114 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 7.691707e-01 | 0.114 | 0 | 0 |
| Immune System | R-HSA-168256 | 7.719166e-01 | 0.112 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 7.740344e-01 | 0.111 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 7.740344e-01 | 0.111 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 7.740344e-01 | 0.111 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 7.740344e-01 | 0.111 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 7.740344e-01 | 0.111 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 7.740344e-01 | 0.111 | 0 | 0 |
| Plasmalogen biosynthesis | R-HSA-75896 | 7.740344e-01 | 0.111 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 7.740344e-01 | 0.111 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 7.740344e-01 | 0.111 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 7.740344e-01 | 0.111 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 7.740344e-01 | 0.111 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 7.740344e-01 | 0.111 | 0 | 0 |
| Uptake of dietary cobalamins into enterocytes | R-HSA-9758881 | 7.740344e-01 | 0.111 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 7.765492e-01 | 0.110 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 7.789651e-01 | 0.108 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 7.814422e-01 | 0.107 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 7.815393e-01 | 0.107 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 7.815393e-01 | 0.107 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 7.847064e-01 | 0.105 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 7.851614e-01 | 0.105 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 7.851614e-01 | 0.105 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 7.851614e-01 | 0.105 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 7.903350e-01 | 0.102 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 7.904014e-01 | 0.102 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 7.905511e-01 | 0.102 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 7.922002e-01 | 0.101 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 7.950331e-01 | 0.100 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 7.953757e-01 | 0.099 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 7.953757e-01 | 0.099 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 7.953757e-01 | 0.099 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 7.953757e-01 | 0.099 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 7.953757e-01 | 0.099 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 7.953757e-01 | 0.099 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 7.953757e-01 | 0.099 | 0 | 0 |
| Estrogen biosynthesis | R-HSA-193144 | 7.953757e-01 | 0.099 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 7.953757e-01 | 0.099 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 7.953757e-01 | 0.099 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 7.953757e-01 | 0.099 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 7.971167e-01 | 0.098 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 7.971167e-01 | 0.098 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 7.971167e-01 | 0.098 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 7.981931e-01 | 0.098 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 7.981931e-01 | 0.098 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 7.981931e-01 | 0.098 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 7.981931e-01 | 0.098 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 8.024918e-01 | 0.096 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 8.044245e-01 | 0.095 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 8.071001e-01 | 0.093 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 8.071001e-01 | 0.093 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.105563e-01 | 0.091 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 8.117017e-01 | 0.091 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 8.117017e-01 | 0.091 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 8.117017e-01 | 0.091 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 8.147026e-01 | 0.089 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 8.147026e-01 | 0.089 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 8.147026e-01 | 0.089 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 8.147026e-01 | 0.089 | 0 | 0 |
| Microbial factors inhibit CASP4 activity | R-HSA-9956593 | 8.147026e-01 | 0.089 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 8.147026e-01 | 0.089 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 8.147026e-01 | 0.089 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 8.147026e-01 | 0.089 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 8.147026e-01 | 0.089 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 8.147026e-01 | 0.089 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 8.218608e-01 | 0.085 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 8.218608e-01 | 0.085 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 8.222726e-01 | 0.085 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 8.253428e-01 | 0.083 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 8.292988e-01 | 0.081 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 8.293249e-01 | 0.081 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 8.322052e-01 | 0.080 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 8.322052e-01 | 0.080 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 8.322052e-01 | 0.080 | 0 | 0 |
| Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA | R-HSA-77310 | 8.322052e-01 | 0.080 | 0 | 0 |
| Beta oxidation of hexanoyl-CoA to butanoyl-CoA | R-HSA-77350 | 8.322052e-01 | 0.080 | 0 | 0 |
| Beta oxidation of octanoyl-CoA to hexanoyl-CoA | R-HSA-77348 | 8.322052e-01 | 0.080 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.322052e-01 | 0.080 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 8.322052e-01 | 0.080 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 8.322052e-01 | 0.080 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 8.322052e-01 | 0.080 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 8.322052e-01 | 0.080 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 8.329534e-01 | 0.079 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 8.333647e-01 | 0.079 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 8.333647e-01 | 0.079 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 8.380881e-01 | 0.077 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 8.380881e-01 | 0.077 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 8.438557e-01 | 0.074 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 8.444814e-01 | 0.073 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 8.453376e-01 | 0.073 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 8.480554e-01 | 0.072 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 8.480554e-01 | 0.072 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 8.480554e-01 | 0.072 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 8.480554e-01 | 0.072 | 0 | 0 |
| Beta oxidation of butanoyl-CoA to acetyl-CoA | R-HSA-77352 | 8.480554e-01 | 0.072 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 8.480554e-01 | 0.072 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 8.480554e-01 | 0.072 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 8.480554e-01 | 0.072 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 8.480554e-01 | 0.072 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 8.488117e-01 | 0.071 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 8.499850e-01 | 0.071 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 8.499850e-01 | 0.071 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 8.499850e-01 | 0.071 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 8.499850e-01 | 0.071 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 8.499850e-01 | 0.071 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 8.532773e-01 | 0.069 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 8.533428e-01 | 0.069 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 8.602319e-01 | 0.065 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 8.610802e-01 | 0.065 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 8.624092e-01 | 0.064 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 8.624092e-01 | 0.064 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 8.624092e-01 | 0.064 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 8.624092e-01 | 0.064 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 8.624092e-01 | 0.064 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 8.624092e-01 | 0.064 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 8.624092e-01 | 0.064 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 8.624092e-01 | 0.064 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 8.624092e-01 | 0.064 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 8.624092e-01 | 0.064 | 0 | 0 |
| Virus Assembly and Release | R-HSA-168268 | 8.624092e-01 | 0.064 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 8.631275e-01 | 0.064 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 8.697824e-01 | 0.061 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 8.701257e-01 | 0.060 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 8.701571e-01 | 0.060 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 8.708901e-01 | 0.060 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 8.714188e-01 | 0.060 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 8.714188e-01 | 0.060 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 8.714188e-01 | 0.060 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 8.714188e-01 | 0.060 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.751387e-01 | 0.058 | 0 | 0 |
| Scavenging by Class B Receptors | R-HSA-3000471 | 8.754078e-01 | 0.058 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 8.754078e-01 | 0.058 | 0 | 0 |
| Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA | R-HSA-77346 | 8.754078e-01 | 0.058 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 8.754078e-01 | 0.058 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 8.754078e-01 | 0.058 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 8.754078e-01 | 0.058 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 8.754078e-01 | 0.058 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 8.754078e-01 | 0.058 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 8.773951e-01 | 0.057 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 8.793111e-01 | 0.056 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 8.818166e-01 | 0.055 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 8.818166e-01 | 0.055 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 8.871791e-01 | 0.052 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 8.871791e-01 | 0.052 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 8.871791e-01 | 0.052 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 8.871791e-01 | 0.052 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 8.871791e-01 | 0.052 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 8.881109e-01 | 0.052 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 8.900003e-01 | 0.051 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 8.971632e-01 | 0.047 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 8.978389e-01 | 0.047 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 8.978389e-01 | 0.047 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 8.978389e-01 | 0.047 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 8.978389e-01 | 0.047 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 8.979433e-01 | 0.047 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 8.983262e-01 | 0.047 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.024178e-01 | 0.045 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.024178e-01 | 0.045 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.025358e-01 | 0.045 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.040867e-01 | 0.044 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 9.043786e-01 | 0.044 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.060616e-01 | 0.043 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 9.060616e-01 | 0.043 | 0 | 0 |
| HDL remodeling | R-HSA-8964058 | 9.074921e-01 | 0.042 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 9.074921e-01 | 0.042 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 9.074921e-01 | 0.042 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 9.074921e-01 | 0.042 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 9.074921e-01 | 0.042 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 9.074921e-01 | 0.042 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.074921e-01 | 0.042 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 9.074921e-01 | 0.042 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.132435e-01 | 0.039 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.136591e-01 | 0.039 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.150513e-01 | 0.039 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.153985e-01 | 0.038 | 0 | 0 |
| Wax and plasmalogen biosynthesis | R-HSA-8848584 | 9.162337e-01 | 0.038 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.162337e-01 | 0.038 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.162337e-01 | 0.038 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.199076e-01 | 0.036 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.207927e-01 | 0.036 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 9.241497e-01 | 0.034 | 0 | 0 |
| Abacavir metabolism | R-HSA-2161541 | 9.241497e-01 | 0.034 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.241497e-01 | 0.034 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.241497e-01 | 0.034 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 9.255033e-01 | 0.034 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.261772e-01 | 0.033 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 9.272034e-01 | 0.033 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 9.313181e-01 | 0.031 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 9.313181e-01 | 0.031 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.313181e-01 | 0.031 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 9.313181e-01 | 0.031 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.313181e-01 | 0.031 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.313181e-01 | 0.031 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.335783e-01 | 0.030 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 9.378093e-01 | 0.028 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.378093e-01 | 0.028 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.378093e-01 | 0.028 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.378093e-01 | 0.028 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 9.378093e-01 | 0.028 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.391127e-01 | 0.027 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.402776e-01 | 0.027 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 9.405028e-01 | 0.027 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.412720e-01 | 0.026 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.412720e-01 | 0.026 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 9.420331e-01 | 0.026 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 9.436875e-01 | 0.025 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 9.436875e-01 | 0.025 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 9.436875e-01 | 0.025 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 9.436875e-01 | 0.025 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 9.436875e-01 | 0.025 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.436875e-01 | 0.025 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.461537e-01 | 0.024 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 9.465789e-01 | 0.024 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 9.465789e-01 | 0.024 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 9.465789e-01 | 0.024 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 9.465789e-01 | 0.024 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.472121e-01 | 0.024 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.472121e-01 | 0.024 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.472121e-01 | 0.024 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.490103e-01 | 0.023 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.490103e-01 | 0.023 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.490103e-01 | 0.023 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.496176e-01 | 0.022 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.507837e-01 | 0.022 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 9.538303e-01 | 0.021 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 9.538303e-01 | 0.021 | 0 | 0 |
| Fertilization | R-HSA-1187000 | 9.538303e-01 | 0.021 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.538303e-01 | 0.021 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 9.546712e-01 | 0.020 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 9.546712e-01 | 0.020 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 9.546712e-01 | 0.020 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.546712e-01 | 0.020 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.553899e-01 | 0.020 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 9.581950e-01 | 0.019 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 9.581950e-01 | 0.019 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.581950e-01 | 0.019 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.581950e-01 | 0.019 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.581950e-01 | 0.019 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 9.581950e-01 | 0.019 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.581950e-01 | 0.019 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.585470e-01 | 0.018 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.585470e-01 | 0.018 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.586209e-01 | 0.018 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.614935e-01 | 0.017 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.615827e-01 | 0.017 | 0 | 0 |
| Synthesis of very long-chain fatty acyl-CoAs | R-HSA-75876 | 9.615827e-01 | 0.017 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 9.621472e-01 | 0.017 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 9.621472e-01 | 0.017 | 0 | 0 |
| Cobalamin (Cbl) metabolism | R-HSA-9759218 | 9.621472e-01 | 0.017 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.621472e-01 | 0.017 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.642422e-01 | 0.016 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 9.646472e-01 | 0.016 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.646472e-01 | 0.016 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 9.657260e-01 | 0.015 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 9.657260e-01 | 0.015 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.657260e-01 | 0.015 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.657260e-01 | 0.015 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.657260e-01 | 0.015 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.668053e-01 | 0.015 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.673630e-01 | 0.014 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.674760e-01 | 0.014 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.676056e-01 | 0.014 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.684761e-01 | 0.014 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.689667e-01 | 0.014 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 9.689667e-01 | 0.014 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.689667e-01 | 0.014 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.706814e-01 | 0.013 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.706814e-01 | 0.013 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 9.719011e-01 | 0.012 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.724936e-01 | 0.012 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.738865e-01 | 0.011 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.742979e-01 | 0.011 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.745582e-01 | 0.011 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.747848e-01 | 0.011 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.763395e-01 | 0.010 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.763774e-01 | 0.010 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.786452e-01 | 0.009 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.786747e-01 | 0.009 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.786954e-01 | 0.009 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.788879e-01 | 0.009 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.788879e-01 | 0.009 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.805475e-01 | 0.009 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 9.806099e-01 | 0.009 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.806099e-01 | 0.009 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.811154e-01 | 0.008 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.821558e-01 | 0.008 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 9.829016e-01 | 0.007 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 9.829016e-01 | 0.007 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.830361e-01 | 0.007 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.845190e-01 | 0.007 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.845190e-01 | 0.007 | 0 | 0 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | R-HSA-2408508 | 9.845190e-01 | 0.007 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.856291e-01 | 0.006 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 9.859834e-01 | 0.006 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.859834e-01 | 0.006 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.859834e-01 | 0.006 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.860565e-01 | 0.006 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.868160e-01 | 0.006 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.872036e-01 | 0.006 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.873094e-01 | 0.006 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.873094e-01 | 0.006 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.873094e-01 | 0.006 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.882586e-01 | 0.005 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.883247e-01 | 0.005 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.885100e-01 | 0.005 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.885100e-01 | 0.005 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.885100e-01 | 0.005 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.902773e-01 | 0.004 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.905814e-01 | 0.004 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.905814e-01 | 0.004 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.914727e-01 | 0.004 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.914727e-01 | 0.004 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.918279e-01 | 0.004 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.921540e-01 | 0.003 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 9.922796e-01 | 0.003 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.929007e-01 | 0.003 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.930102e-01 | 0.003 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.936718e-01 | 0.003 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.942707e-01 | 0.002 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.946291e-01 | 0.002 | 0 | 0 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | R-HSA-77286 | 9.948130e-01 | 0.002 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.950800e-01 | 0.002 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 9.956203e-01 | 0.002 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.957468e-01 | 0.002 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.961510e-01 | 0.002 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.962213e-01 | 0.002 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.965404e-01 | 0.002 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.965404e-01 | 0.002 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.968331e-01 | 0.001 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 9.969355e-01 | 0.001 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.971440e-01 | 0.001 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.971440e-01 | 0.001 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.976395e-01 | 0.001 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.976593e-01 | 0.001 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.981413e-01 | 0.001 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.982196e-01 | 0.001 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.982634e-01 | 0.001 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.983577e-01 | 0.001 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.985783e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.987945e-01 | 0.001 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.988337e-01 | 0.001 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.989442e-01 | 0.000 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.990723e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.991017e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.991235e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.991348e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.992168e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.992792e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.994741e-01 | 0.000 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.994741e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.995546e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.995979e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.996099e-01 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.996099e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.996648e-01 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.996804e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.997107e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.997206e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.997381e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.997414e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.997672e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.998058e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.998170e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.998242e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.998242e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.998436e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.998517e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.998527e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.998560e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999208e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999226e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999293e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999356e-01 | 0.000 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.999414e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999597e-01 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 9.999736e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.999771e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999880e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999914e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999956e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999959e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999966e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999967e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999984e-01 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 9.999988e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999988e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999992e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999994e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999996e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999998e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999998e-01 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 9.999999e-01 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.999999e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |